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CHAPTER ONE 
GENERAL INTRODUCTION 
Brain Tumors: Types, Grades, Incidence, Survival, and Current Therapies 
The Human Brain - The human nervous system is broadly divided into the central 
nervous system (CNS) and the peripheral nervous system (PNS).  The CNS is 
composed of the brain and spinal cord, whereas the PNS is the collection of spinal and 
cranial nerves that infiltrate all parts of the body, conveying messages to and from the 
CNS (Nolte and Sundsten, 2002).  The CNS is covered by a tri-layered structure called 
the meninges, and is constantly bathed in cerebrospinal fluid (CSF) that is produced by 
the choroid plexus deep within the brain’s ventricular system and reabsorbed by 
arachnoid granulations along the superior sagittal sinus. 
Generally speaking, there are two major classes of cells in the human nervous 
system: neurons and glial cells; the latter provide a supporting function for the impulse 
transmission, structure, and the general function of the former.  There are two major 
classes of glia in the vertebrate nervous system: microglia and macroglia.  Microglia 
arise from macrophages outside of the nervous system and serve a phagocytic role. 
There are three types of macroglial cells: oligodendrocytes, Schwann cells, and 
astrocytes.  Oligodendrocytes and Schwann cells myelinate axons of nerve cells 
thereby greatly increasing nerve conduction velocity along said axons; the former 
myelinate CNS neurons and the latter myelinate PNS neurons. Oligodendrocytes may 
myelinate the axons of several different neurons in their immediate vicinity, whereas 
Schwann cells only myelinate one axon.  Astrocytes are the most numerous of all the 
glial cells, owing their name to their predominantly star-shaped cell bodies.  Astrocytes 
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perform a wide range of roles in the nervous system including maintenance of the 
blood-brain barrier, mediation of extraneuronal ion concentrations and neuronal 
homeostasis, and to some extent (albeit indirectly) participation in cell signaling.  Nerve 
cells, or neurons, are the main signaling units of the nervous system.  A neuron has 4 
morphologically defined regions: dendrites, a cell body, the axon, and presynaptic 
boutons.  Dendrites serve to take in electrical information from other neurons in the form 
of post-synaptic potentials (these may be excitatory or inhibitory).  At any given time all 
of these individual potentials combine to form one large potential (through, for example, 
“spatial” or “temporal” summation) which is then transmitted to the initial segment of the 
neuronal axon (the “axon hillock).  If this potential is of sufficient strength, it will trigger 
depolarization of the axon hillock and initiate a nerve impulse down the axon into the 
presynaptic terminals where this electrical energy is converted to chemical energy 
through the voltage-dependent release of synaptic vesicles containing 
neurotransmitters.  These neurotransmitters are released into the synaptic cleft 
(separating the presynaptic terminals of one neuron from the postsynaptic receptors of 
another) and can have a variety of effects on the next neuron (Kandel et al., 2000). 
Tumors of the PNS or CNS can arise from virtually any of the aforementioned 
brain structures.  For example, there are tumors of the meninges (termed 
“meningiomas”), tumors of the peripheral nerves and associated glial cells 
(Schwannomas, neurofibromas, and the like), tumors of the nerves themselves 
(“gangliocytomas”, “neurocytomas”), and tumors of the glial cells (astrocytomas, 
oligodendrogliomas, etc.).  It is these tumors of the glial cells that is the central focus of 
my research; in particular one of the most severe forms of astrocytoma in existence 
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(glioblastoma). 
Classification of Brain Tumors - The revised WHO Histological Typing of Tumors of 
the Central Nervous System (Louis and International Agency for Research on Cancer., 
2007) classifies astrocytic tumors as tumors of neuroepithelial tissue.  Tumors of 
neuroepithelial tissue are subdivided into nine categories: astrocytic, oligodendroglial, 
ependymal, mixed glial, choroid plexus tumors, neuroepithelial tumors of uncertain 
histogenesis, neuronal and mixed neuronal-glial tumor, pineal tumor, and embryonal 
tumor.  Astrocytic tumors, in turn, are subdivided into six groups: diffuse astrocytoma, 
anaplastic astrocytoma, glioblastoma, pilocytic astrocytoma, pleomorphic 
xanthoastrocytoma, and subependymal giant cell astrocytoma. 
The WHO also classifies tumors of cranial and paraspinal nerves, including 
Schwannoma, neurofibroma, perineuroma, and malignant peripheral nerve sheath 
tumor (MPNST).  Also classified by the WHO are tumors of the meninges 
(meningothelial cell tumors, mesenchymal tumors, primary melanocytic lesions, and 
other), and lymphomas, germ cell tumors, sellar region tumors, and metastatic lesions.  
Tumor Grading - The WHO has implemented a grading scheme for CNS tumors that 
serves as a “malignancy scale” in order to evaluate these tumors.  For a given CNS 
tumor there are 4 WHO grades possible, simply classified as WHO grade I, II, III, or IV. 
WHO grade I lesions generally include tumors with low proliferative potential and 
possibility of cure with surgical resection alone.  There are only 2 astrocytic tumors that 
fit this grade: subependymal giant cell astrocytoma (SEGA) and pilocytic astrocytoma. 
Other examples (to name a few) of WHO grade I tumors include meningioma, 
subependymoma, and choroid plexus papilloma.  WHO grade II tumors are generally 
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infiltrative in nature and tend to recur despite gross total surgical resection.  These 
lesions also tend to progress to higher grades of malignancy.  Examples of WHO grade 
II tumors include diffuse astrocytoma, oligodendroglioma, ependymoma, atypical 
meningioma, and hemangiopericytoma.  A tumor that has earned the grade of WHO 
grade III exhibits histological evidence of malignancy (specifically nuclear atypia and 
abundant mitotic figures).  Anaplastic astrocytoma, anaplastic oligodendroglioma, and 
anaplastic meningioma are all examples of WHO grade III lesions. WHO grade IV 
lesions are cytologically malignant, mitotically active, necrotic neoplasms usually 
associates with rapid progression of disease and poor outcome.  Medulloblastoma, 
glioblastoma, and pineoblastoma are all examples of WHO grade IV tumors (Louis and 
International Agency for Research on Cancer., 2007). 
With the aforementioned exceptions of SEGA and pilocytic astrocytoma, the 
grading of astrocytic tumors are graded in a 3 tiered system based on their histology.  
Tumors with cellular atypia alone are WHO grade II (diffuse astrocytoma); tumors also 
showing anaplasia and mitotic activity are WHO grade III (anaplastic astrocytoma), and 
tumors additionally showing necrosis and/or microvascular proliferation are WHO grade 
IV.  There are 3 astrocytic tumors that are WHO grade IV lesions: glioblastoma, 
gliosarcoma, and giant cell glioblastoma (Louis and International Agency for Research 
on Cancer., 2007).  Glioblastoma is characterized microscopically by necrosis and/or 
endothelial cell proliferation coupled with increased cellularity, mitotic figures and 
pleomorphism (Kaye and Laws, 2001; Kleihues and Sobin, 2000). 
Epidemiology of Primary Brain Tumors - The incidence of primary malignant or 
benign brain tumors in the United States is 18.71/100,000 person-years; while 
  
5
7.19/100,000 are diagnosed with a malignant brain tumor, 11.52/100,000 are non-
malignant.  There are about 13,000 deaths annually from these tumors, placing brain 
malignancies among the top 10 leading causes of cancer-related deaths. 4.71/100,000 
children will have a primary brain tumor before age 20 years.  The distribution of primary 
brain tumors in the general population is strongly age specific.  The incidence rates are 
higher in pediatric males (4.75/100,000 male vs. 4.66/100,000 female) and in adult 
females (19.88/100,000 female vs. 17.44/100,000 male).  The incidence rate of primary 
malignant brain tumors, however, is higher in males than in females (7.6/100,000 male 
vs. 5.4/100,000 female) (Wrensch et al., 2002).  Gliomas and other neuro-epithelial 
tumors constitute 49% of primary brain tumors, while meningiomas are the second most 
common type (27%).  Specifically looking at histology, meningioma is the most common 
type at 33.8%, followed by glioblastoma (17.1%) and pituitary (12.7%) (Wrensch et al., 
2002). 
The probability of histological malignancy in an astrocytoma is 0.34 between 30-
34 years and 0.85 after the age of 60.  The incidence of glioblastoma and astrocytoma 
per 100,000 population rises from 0.2 and 0.5 in the under-age 14 group to 4.5 and 1.7 
(respectively) after the age of 45.  Along with the age-related shift in histology we also 
see a shift in location: Under the age of 25 years, 67% of astrocytomas are infratentorial 
(in other words, in the brainstem or cerebellum) whereas over the age of 25 years 90% 
are supratentorial (in the cerebral cortex, basal ganglia, diencephalon, deep white 
matter, etc.).  The terms “supratentorial” and “infratentorial” refer to the “tentorium”: a 
leaflet of dura separating the cerebellum from the cerebral cortex.  In the USA, 
glioblastoma occurs at the greatest mean age of all brain tumors (60.2 years). In most 
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series there is a slight preponderance of males observed for glioblastoma incidence 
(Kaye and Laws, 2001). 
Survival - The 5 year relative survival rate of a primary brain tumor is 33.6% in males 
and 37% for females.  Broken down by age, 5 year relative survival rates are as follows: 
0-19 years = 72.1%, 20-44 years = 55.9%, 45-54 years = 30.7%, 55-64 years = 16.7%, 
65-74 years = 9.6%, and age 75 or older = 5.2% (CBTRUS data: 
http://www.cbtrus.org/2007-2008/2007-20081.html).  Survival rate is closely tied in with 
tumor histology, and glioblastoma has one of the worst 5-year survival rates of all the 
brain tumors.  To illustrate: 5-year survival rates for pilocytic astrocytoma = 94%, for 
oligodendroglioma = 79%, for anaplastic oligodendroglioma = 47%, and for anaplastic 
astrocytoma = 27%. The 5-year survival rate for glioblastoma = 4.46%. 
Glioblastoma - Glioblastoma is the most common, and unfortunately the most deadly, 
malignant primary brain tumor.  Current medical and surgical therapies only minimally 
prolong life expectancy and improve quality of life and are generally ineffective at 
specifically addressing the underlying pathology.  The primary reason for this is that by 
the time patients present with a Glioblastoma, the tumor has already microscopically 
spread to other areas of the brain outside of the grossly obvious tumor location.  
Successful treatment of Glioblastoma must therefore directly address unique 
characteristics of the individual tumor cell on a molecular level as well as the 
macroscopic elements of the tumor.  Effective treatment of Glioblastoma will most likely 
be a combination of surgical intervention directed at grossly reducing the size of the 
tumor itself (gross tumor debulking, BCNU implantation, radiotherapy and radiosurgery, 
etc.) and molecular techniques that target the tumor cells individually (vaccines and 
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immunotherapy, viral vectors and gene therapy, etc.). 
Current Therapies for Glioblastoma - The current standard-of-care for operable 
glioblastoma includes surgical resection followed by radiation and chemotherapy 
(Sathornsumetee et al., 2007).  Several factors determine whether a glioblastoma is 
operable or inoperable. In general, if the tumor is of the “butterfly” type (i.e. invading the 
corpus callosum and both hemispheres) or infiltrating the deep brain structures 
(hypothalamus, basal ganglia, etc.), then the tumor is usually deemed inoperable.  Once 
the diagnosis of glioblastoma has been established, a craniotomy and extensive tumor 
debulking surgery should be performed with the goal of removing as much tumor as 
surgically possible while maintaining the integrity of the surrounding and intervening 
structures that are absent of any gross tumor invasion.  Gross total or near-total 
resection has been shown to increase survival (Cavaliere et al., 2007) significantly 
(Lacroix et al., 2001).  As an adjunct, post-surgical radiation therapy is administered in 
1.5 to 2 Gy fractions to a total dose of 58 to 60 Gy to the tumor bed or resection cavity 
with a 2-3 cm margin (Sathornsumetee et al., 2007).  There are several 
chemotherapeutic agents used as adjuvant therapy in GBM.  Nitrosoureas such as 
carmustine/BCNU are lipophilic agents that readily cross the blood-brain barrier and 
form cross-links in DNA.  BCNU-impregnated wafers (Gliadel) may be implanted in the 
resection cavity after gross total GBM resection.  BCNU has been shown to increase 
eighteen month survival, but not median survival, in patients status-post GBM resection 
(Cavaliere et al., 2007).  Temozolomide (Temodar) is an oral methylating agent with 
near 100% bioavailability.  Temozolomide methylates DNA at the O6 position of 
guanine which results in base pair mismatch during replication.  Clinicians had high 
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hopes for temozolomide use in conjunction with radiation therapy for GBM patients, 
however median survival increase has been shown to be modest (14.6 months vs. 12.1 
months) (Robins et al., 2007).  Irinotecan is a water soluble camptothecin derivative that 
inhibits topoisomerase I, preventing re-ligation of DNA following single strand breaks.  It 
has been studied extensively in patients with recurrent GBM and in combination with 
other agents such as BCNU and temozolomide. Irinotecan has been shown to 
potentiate the activity of both BCNU and temozolomide when administered in 
combination (Cavaliere et al., 2007).  Bevacizumab (Avastin) is a monoclonal Ig(G) 
antibody that binds to and inhibits human VEGF-A. It has shown some promise in GBM 
patients, especially in combination with irinotecan (Cavaliere et al., 2007). 
As stated in the introduction, the aforementioned conventional management of 
patients with glioblastoma is generally unsatisfactory because an algorithmic treatment 
plan cannot deal with the extreme cellular heterogeneity and therapeutic resistance of 
the tumor.  None of the above adjunctive or adjuvant treatments has been shown to 
significantly increase median survival of GBM patients.  Future treatment plans must be 
tailored to adapt to the wide diversity of cells in a solid glioblastoma as well as 
associated micrometastases (Kaye and Laws, 2001). 
Metabolism of Glioblastoma vs. Normal Brain 
Normal Brain Metabolism - The brain is a unique organ in that it relies solely on 
glucose (and ketone bodies in case of starvation) for energy.  It keeps no glycogen or 
fat storage, and so in essence is an “end organ” with regards to substrate.  Since the 
brain relies solely upon blood glucose, substrate supply is thus a function of cerebral 
blood flow (Kaye and Laws, 2001). 
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Under normal circumstances, average human cerebral blood flow is 45 to 60 
ml/100 grams of brain/minute, representing roughly 15% of cardiac output.  Flow is 
maintained across a wide range of perfusion pressures by the process of 
autoregulation, allowing adequate substrate delivery (O2 and glucose, predominately) to 
meet metabolic demands.  The normal cerebral metabolic rate of oxygen is 
approximately 3.5 ml/100 grams of tissue/min (20% of resting total body O2 
consumption).  The majority of this oxygen is used by the normal brain to generate 
energy through the aerobic metabolism of glucose (Zauner et al., 2002). 
 The first step in the cellular metabolism of glucose is the process of 
glycolysis (Figure 1).  Glucose is transported from the bloodstream into the brain by 
carrier-mediated transport across the blood-brain barrier by the GLUT-1 transporter and 
then into neurons by the GLUT-3 transporter (GLUT-1 in astrocytes). 
 
 
 
Figure 1: Excess hydrogen ions as by-products of metabolic processes are 
shunted out of the cytosol by lactate transporters and other ion exchange
proteins in the cell membrane (Gatenby and Gillies 2004).
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Once inside of the cell, D-glucose is phosphorylated by the enzyme hexokinase 
(HK) to glucose 6-phosphate. HK has a low Km (and therefore a high affinity) for D-
glucose, allowing for efficient metabolism of glucose even in low tissue quantities.  HK is 
down-regulated by its metabolic product, glucose 6-phosphate, as well as increased 
ATP/ADP ratios (which essentially are one in the same, since the metabolic 
intermediates of glycolysis like glucose 6-phosphate will accumulate in the cell if energy 
stores are high and downstream metabolic processes slow down).  The rate-limiting 
enzyme of glycolysis is phosphofructokinase-1 [PFK-1], which is activated by 
intracellular AMP levels (an indicator of increased ATP usage). It catalyzes the 
irreversible phosphorylation of fructose 6-phosphate to fructose 1,6-bisphosphate. ATP 
and citrate (indicators of high amounts of energy stores) are allosteric inhibitors of PFK-
1 (Mangiardi and Yodice, 1990).  The final step in glycolysis is also the final regulatory 
step, and it is catalyzed by pyruvate kinase (PK).  PK converts phosphoenolpyruvate to 
pyruvate.  Fructose 1,6-bisphosphate is a strong activator of PK (feed-forward 
regulation effectively links the kinase activities of PKF-1 ad PK) (Figure 2).  
Under normal circumstances, the pyruvate that is generated by glycolysis is then 
shunted into the Citric Acid Cycle [TCA cycle or Krebs Cycle].  Pyruvate that is not used 
in the TCA cycle is reduced by lactate dehydrogenase and NADH to form lactate 
(anaerobic glycolysis) or converted into the amino acid alanine. Pyruvate then enters 
the mitochondria where it can enter the TCA cycle as either acetyl coenzyme A (main 
path) or oxaloacetate.   
In the TCA cycle, acetyl coenzyme A and oxaloacetate are metabolized to form 
NADH and FADH2 which then enter the electron transport chain [ETS] to generate ATP.  
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The  TCA  cycle  is  also  regulated  in response to metabolic demands; its  rate  limiting  
 
 
enzyme is isocitrate dehydrogenase which is activated by ADP and inhibited by NADH. 
(Berg et al., 2006; Zauner et al., 2002) (Figure 3).  According to the chemiosmotic 
hypothesis, the mitochondria use electrons donated by NADH and FADH2 to pump 
hydrogen ions across inner mitochondrial (hydrogen ion-impermeable) membrane into 
the intermembrane space of the mitochondrion using a series of transport proteins.  The 
electron is passed from complex I to III and IV, creating a hydrogen ion gradient across 
the inner mitochondrial membrane.  When the electron reaches complex IV (cytochrome 
Figure 2: In normal cells, glycolysis is regulated at 3 steps (PFK-1, HK, PK).  In 
malignant tumor cells, these enzymes fail to respond to normal metabolic signals and
are constitutively activated, leading to uncontrolled lactate production.
(http://138.192.68.68/bio/Courses/biochem2/Gluconeogenesis/GluconeogenesisResources/GlycolysisGlu
coNeo.gif) 
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oxidase), the electron is donated to O2 giving H2O. Complex V (F0/F1-ATP synthase) 
then uses the ion gradient to generate ATP from ADP and Pi.  The net (theoretical) yield 
of this process of oxidative phosphorylation is 38 ATP, 6 CO2, and 6 H20 per 1 mole of 
glucose (Zauner et al., 2002) although in practice approximately 30 ATP are made due 
to proton leakage across the inner-mitochondrial membrane (Berg et al., 2006).  
 
 
 
 
 
 
 
In mammalian cells, glycolysis is inhibited by the presence of oxygen, which 
allows mitochondria to fully oxidize pyruvate to CO2 and H2O.  This inhibition is referred 
to as “the Pasteur effect” after Louis Pasteur who was the first to demonstrate that 
glucose flux was reduced by the presence of oxygen (Gatenby and Gillies, 2004).  
However, even since the early 1920’s researchers like Otto Warburg had observed that 
many tumor cells metabolized glucose in a very different way. Modern positron-
emission tomography (PET) using fluorodeoxyglucose (FdG) has shown that most 
primary and metastatic tumors show significantly increased glucose uptake as 
compared to normal cells, a so-called “glycolytic phenotype” (Gatenby and Gillies, 2004; 
Pedersen, 1978).  This phenotype seems to manifest itself through up-regulated 
  
Figure 3: Glycolysis takes place in the cytosol of mammalian cells, while the Krebs cycle
and the electron transport chain take place in the mitochondria (Zauner, Daugherty et al. 
2002). 
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glucose transport into malignant cells (via up-regulation of GLUT-1 and GLUT-3 glucose 
transporters on the cell surface) and an up-regulated phosphorylation step (Glucose to 
glucose-6-phosphate, catalyzed by hexokinase).  Tumor cells have been shown to 
maintain this glycolytic phenotype in culture under normoxic conditions, and the rate of 
glycolysis in cultured cell lines seems to linearly correlate with tumor aggressiveness 
(Gatenby and Gillies, 2004).  Furthermore, it appears that may malignant cell lines 
exhibit what is known as the “Crabtree effect”: In the presence of glucose, oxygen 
consumption in tumor cells is impaired (in essence, the opposite of the Pasteur effect) 
(Argiles and Lopez-Soriano, 1990). 
Metabolism of the Malignant Astrocytoma - The term anaplasia refers to a process of 
malignant change which may occur in any tissue type.  The process of anaplasia 
includes several survival mechanisms that allow a neoplasm to compete successfully 
with its host. These include: 
1. Utilization of primitive enzyme systems that give the tumor energy management 
and growth advantages over the host 
2. Tumor vs. host products such as tissue lytic enzymes, immune-suppressors, 
growth factors, etc. 
3. Extracellular matrix modifications including pH, oxygen tension level alteration, 
and perfusion change 
4. Cell membrane alterations including antigenic mutation, second messenger 
enhancements 
5. Autoinduction (A process by which a tumor cell virtually guarantees its own 
unrestrained growth and replication) 
  
14
The above mechanisms allow malignant brain tumors to gain a survival 
advantage over their hosts and replicate beyond the control of the host immune system.  
This certainly puts the host at a clear disadvantage when attempting to combat a brain 
tumor, however because many of these processes are unique to tumor cells they offer 
significant targets for potential antitumor therapies (Kaye and Laws, 2001). 
Since the 1930s there has been a great deal of research comparing the 
metabolism of malignant astrocytes to that of normal astrocytes.  As I will presently 
explain, this research has shown that the metabolic processes of malignant astrocytes 
are much different from those of normal cells, and this difference is thought to augment 
the malignant cell’s chance for survival in an otherwise normal host environment. 
Every cellular metabolic process can be traced back to genetic information stored 
in a cell’s DNA.  The information encoded on DNA is copied to messenger RNA [mRNA] 
are then exported from the nucleus to the cytosolic rough endoplasmic reticulum where 
it is translated into proteins by the ribosomes.  The most crucial proteins are the 
enzymes since they are responsible for the production of the metabolic and structural 
machinery of the cell.  In neoplastic cells, changes have occurred to allow for the 
introduction of a new genetic code into the cellular DNA, duplication and amplification of 
existing portions of the code, and/or the unmasking of normally repressed genes in the 
code.  Certain genes in the code are referred to as proto-oncogenes in that they are 
normal portions of the genetic code that control cell proliferation, maturation and 
differentiation.  Once these genes are activated, they become oncogenes and can result 
in the neoplastic transformation of a normal cell through the action of the peptide that it 
codes.  Processes that convert proto-oncogenes into oncogenes include gene mutation, 
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amplification, and translocation or rearrangement.  Expression of genes that were 
previously silent can lead to the presence of an entirely different set of metabolic 
machinery in cancer cells that can, in part, explain their strange behavior when 
compared to normal cells. Indeed, researchers have recently discovered a molecule 
called hypoxia inducible factor-1 alpha (HIF-1).  HIF-1 is widely overexpressed across a 
broad range of cancers and is thought to control cellular and systemic responses to 
oxygen availability and coordinates up-regulation of genes involved in many pathways 
concerned with tumor growth and metabolism, cellular proliferation, differentiation and 
viability, apoptosis, pH regulation, and matrix metabolism (Stubbs et al., 2003).  
Specifically, it induces survival genes such as glucose transporters, angiogenic growth 
factors (for example, vascular endothelial growth factor [VEGF]), hexokinase II, and 
hematopoietic factors (for example, transferrin and erythropoietin [EPO]) (Gatenby and 
Gillies, 2004).  Interestingly, a mutation in the von Hippel-Lindau (VHL) ubiquitin ligase 
produces constitutively high expression of HIF-1, as the wild type protein marks HIF-2 
for proteasomal degradation.  Re-insertion of transgenic VHL restores normal levels of 
HIF-1 and (not coincidentally) greatly reduces aerobic glucose consumption rates.  
Although significant, hypoxia is not the only factor that can stabilize HIF-1 in tumor cells. 
Other examples include cyclooxygenases, heat shock proteins, insulin-like growth 
factors, and thioredoxin (Gatenby and Gillies, 2004).  This may help explain how 
malignant tumor cells have such a different pattern of metabolism than normal host 
cells, for example, constitutive up-regulation of glycolysis is likely to be (in part) an 
adaptation to hypoxia that develops as pre-malignant lesions grow progressively further 
from their blood supply (Gatenby and Gillies, 2004).  This is unlikely to be solely a result 
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of hypoxia, since this malignant phenotype of up-regulated glycolysis is seen in 
normoxic conditions in tumor cells and rapidly dividing host cells.  Many researchers 
feel, however, that this glycolytic phenotype is necessary for malignant tumor evolution 
and invasion. 
Tumors, especially malignant tumors, were once though to rely solely on glucose 
and/or glutamine for metabolic fuel.  It wasn’t until recently that researchers began to 
realize that tumor cells may draw upon a wide range of fuels, for example fatty acids, 
amino acids (other than glutamine), and ketone bodies.  In fact, when MCF-7 breast 
cancer cells were examined in culture, researchers found that glucose and glutamine 
were significant fuels but only accounted for less than half of total ATP turnover (Guppy 
et al., 2002). 
Aerobic Glycolysis - The mean ATP and total adenylate levels in astrocytic tumors 
have been shown to be significantly higher than in surrounding brain.  This is explained 
logically by the fact that malignant astrocytomas have to satisfy both basic metabolic 
demands and tumor growth.  As previously described, normal cells prefer to utilize 
oxygen to fully metabolize glucose using oxidative phosphorylation, but in situations 
where O2 is in short supply, normal astrocytes will metabolize pyruvate using lactate 
dehydrogenase into lactate and 2 moles of ATP (anaerobic glycolysis).  Neuronal 
neoplasms have been shown to do something much different: they preferentially 
metabolize pyruvate into lactate even when O2 is present in excess.  O2 consumption is 
reduced, and although only 2 ATP per mole of glucose is produced by this process, 
significant stores of ATP are still present.  This process was discovered by Otto 
Warburg and is now known as aerobic glycolysis or the Warburg effect (Warburg, 
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1956).  This process is thought to confer upon the malignant astrocyte the ability to 
thrive whether oxygen is present or not, so long as there is a steady supply of glucose.  
As a consequence of this process, the metabolic activity of brain neoplasms must be 
assessed in terms of glucose uptake rather than O2 consumption.  Not surprisingly, 
positron emission tomography scans of astrocytomas show that cerebral glucose 
uptake and consumption by tumor may be up to 3 times that of normal brain.  
 
 
 
The Glycolytic Pathway - In 1956, after observing the high rates of glycolysis in many 
aggressive tumor cells and noting the absence of the Pasteur effect, Otto Warburg 
hypothesized that rapid anaerobic glycolysis was the primary explanation of malignancy 
(Warburg, 1956).  This hypothesis has since been disproven by many observations, for 
example, many tumor cells utilize other substrates besides glucose (including lipids, 
Figure 4: In tumor cells, hexokinase is found to be closely associated with the
mitochondrial membrane. (Mathupala, Ko et al. 2006). 
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amino acids, and ketones).  Furthermore, relative rates of glycolysis of some normal 
tissues overlap with the rates of glycolysis in tumor cells (such as rapidly dividing 
tissues in the gut, and in the embryo).  Finally, mutant cell lines incapable of glycolysis 
have still retained their malignant characteristics (Dills, 1993). Nevertheless, rapid 
glycolysis is a frequent characteristic of malignant tumor cells.  As we will discuss, there 
are several molecular reasons for the enhanced glycolysis in tumor cells. 
Changes in Enzymes and Metabolic Patterns - Recall that the three rate-limiting 
enzymes of the glycolytic pathway are PFK-1, HK, and pyruvate kinase.  A few 
researchers have published results showing a 30% to 60% decrease in PFK-1 activity 
and a 29% to 40% decrease in hexokinase activity in fresh GBM homogenates (Lowry 
et al., 1983; Marzatico et al., 1986).  However, the vast majority of literature has shown 
a significant increase in the activity of each of the key regulatory enzymes in glycolysis 
in tumor cells (Argiles and Lopez-Soriano, 1990, 1998; Argiles and zcon-Bieto, 1988; 
Baggetto, 1992; Dills, 1993; Floridi et al., 1989; Gatenby and Gillies, 2004; Rodriguez-
Enriquez and Moreno-Sanchez, 1998).  These changes in enzyme activity appear to be 
unrelated to ATP or citrate levels, implying that in neoplasms, these enzymes are 
fundamentally different than they are in normal cells (either in cofactor requirements or 
in structure).  Strong evidence supports the finding that the glycolytic rate is elevated in 
malignant tumors; modern day fdG PET studies have confirmed the massive increase in 
glucose metabolism in a great many brain tumors. 
x Hexokinase:  The Km of hexokinase for glucose in tumor cells is even lower 
than that of wild-type HK (isoform II predominates in tumor cells, whereas type IV 
is seen in WT).  HK exists in two forms in tumor cells: a cytosolic form and a 
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mitochondrial bound form.  This is thought to confer a metabolic advantage to 
tumor cells, harnessing ATP generated from oxidative phosphorylation and 
shunting it directly into glycolysis (Figure 4). 
x Phosphofructokinase-1: The rate-limiting enzyme of glycolysis in normal cells, 
PFK-1 activity is much increased in tumor cells.  This is thought to be a result of 
a rise in lactic acid levels that increase the proton concentration in the cytosol 
(decreasing pH), which in turn stimulates PFK-1 (Rodriguez-Enriquez and 
Moreno-Sanchez, 1998).  Furthermore, fructose 6-phosphate (a potent activator 
of PFK-1) is present in large amounts due to increased HK activity.  This 
overcomes any inhibition that ATP may have on PFK-1, and the resulting 
fructose 1,6-bisphosphate activates not only PFK retroactively, but also PK 
proactively. 
x Pyruvate Kinase: PK is a tetramer that may exist as different isozymes made up 
of either K or M subunits.  The K or M2 type is dominant in fetal life, and is the 
only isoform found in malignant gliomas.  M type is found in normal adult cells 
(Tolle et al., 1976)  The M2 fetal type PK is strongly inhibited by alanine and 
activated strongly by fructose 1,6-bisphosphate.  The result is rapid conversion of 
phosphoenolpyruvate to pyruvate by PK. 
x Lactate Dehydrogenase: Lactate dehydrogenase activity is the same in tumor 
cells as it is in wild type cells, explaining the relatively high lactate levels found in 
and around tumors in situ.  As we will soon discuss, the greatly reduced 
NAD+/NADH ratio in tumor cells greatly favors the rapid conversion of pyruvate 
to lactate. 
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It has been proposed that these isoenzymatic pattern changes are part of a 
metabolic strategy that tumor cells enact in order to survive in a low oxygen 
environment.  There are currently three hypotheses that attempt to explain this 
observed phenomenon: A) gene mutation leads to isoenzymatic changes in key 
regulatory enzymes of glycolysis (PFK-1 and HK) which then lead to a change in the 
way these enzymes react to positive and negative stimuli; B) glycolysis is accelerated 
due to lack of activity in the transference systems of cytosolic reducing equivalents to 
mitochondria (malate/aspartate and glycerol-3-phosphate shuttles) resulting in 
conversion of much of the pyruvate from glycolysis into lactic acid, further decreasing 
cytosolic NADH oxidation, and C) the complex of pyruvate dehydrogenase is 
competitively inhibited by acetoin (a 4-carbon metabolite resulting from pyruvate non-
oxidative decarboxylation) (Rodriguez-Enriquez and Moreno-Sanchez, 1998). 
Enhanced Glucose Uptake - One of the contributing factors to enhanced glucose 
utilization in tumors is an increase in glucose uptake into the tumor cells.  Most studies 
confirm that there is a significant increase in the numbers of the GLUT transporters in 
malignant cells.  Furthermore, increases in glucose uptake into tumor cells may also be 
a result of the increased concentration gradient of glucose driving the molecule into 
cells (due to rapid glycolysis and lactic acid production inside of the cell) (Dills, 1993). 
Lack of a Pasteur effect and Mitochondrial Content - Most tumor cells have a 
reduced or absent Pasteur effect, most likely due to lack of competition for ADP 
between glycolysis and respiration (as a result of the aforementioned changes in tumor 
glycolysis).  Quite interestingly, it has been shown that the actual mitochondrial content 
of many of the fastest growing tumors is quite low (in concert with the observation of low 
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oxygen uptake by these same cells) (Dills, 1993). 
The NADH Shuttles - Under normal circumstances, the NADH generated from the 
glycolytic pathway is normally shunted into the mitochondria for oxidation by several 
shuttles (malate/aspartate, glycerol-phosphate, or fatty acid cycle).  In tumor cells, these 
shuttles are apparently impaired, and as a consequence NADH levels increase in the 
cytosol, leading to further lactate metabolism and NADH reduction in the cytosol.  
However, this appears to play a very minor role in excess lactate production since 
several researchers have shown that the shuttles (for example, the malate/aspartate 
shuttle) in several tumor cell lines is sufficient to fully re-oxidize cytosolic NADH 
(Greenhouse and Lehninger, 1976).  
The ATP Synthase Activity of a Cell as Modulator of Glycolysis - Since ADP acts 
directly on the PK step of glycolysis as an up-regulator, it stands to reason that 
increased ATP synthase activity would serve to increase the rate of glycolysis by 
providing higher amounts of ADP to act at the PK step.  Not surprisingly, ATP/ADP 
ratios have been shown to be significantly lower in several types of tumor cells.  
Furthermore, a defective Na/K ATPase has been discovered in tumor cells that acts 
with a high amount of inefficiency (increased ATP hydrolysis/Na extrusion ratio), 
apparently due to phosphorylation of the enzyme by a tyrosine kinase present in the 
membrane (Argiles and Lopez-Soriano, 1990). 
The Citric Acid Cycle and Oxidative Phosphorylation - In malignant astrocytomas 
the activities of citrate synthetase and malate dehydrogenase are markedly decreased, 
while the activity of succinate dehydrogenase appears to be equal to that of normal 
cells.  The result of this is that less acetyl-CoA is used by a less active TCA cycle.  
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Pyruvate will then accumulate (forming abnormally high levels of lactic acid) and NADH 
is not produced (so O2 is not consumed by oxidative phosphorylation).  Many 
researchers have concluded that the grade of malignancy of an astrocytoma is inversely 
related to its cytochrome oxidase activity (Allen, 1957, 1972).  Other researchers have 
discovered a “truncated” TCA cycle in various malignant tumors.  In these cells, citrate 
does not continue its oxidation because the aconitase and isocitrate dehydrogenase 
enzymes have low activity.  Citrate is therefore actively released from the mitochondria 
where it is used for sterol/cholesterol synthesis in the cytosol (Rodriguez-Enriquez and 
Moreno-Sanchez, 1998) (Figure 5). 
 
Figure 5: The citric acid cycle. In malignant tumors, the citric acid cycle is “truncated”, 
and citrate is shunted out of the mitochondria and used for sterol synthesis in the 
cytosol. (©Dr. Noel Sturm 2009 http://chemistry.gravitywaves.com/CHE452/SyllabusCHE452SP09.htm) 
 
The Pentose Phosphate Pathway (Pentose Shunt or PPP) - The purpose of the 
pentose shunt is to metabolize glucose-6 phosphate (a glycolytic intermediate) via 
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glucose-6 phopsphate dehydrogenase (the rate limiting enzyme of the PPP) to 
phosphoribosylpyrophosphate (PRPP) which is a precursor for purine and pyrimidine 
synthesis.  Presumably because of the forward need for nucleic acid synthesis in rapidly 
dividing tumor cells combined with the fact that most of the metabolic pathways 
downstream of glycolysis are working so slowly, the activity of glucose-6 phosphate 
dehydrogenase has been found to be more than 280% that of normal brain.  
Gluconeogenesis in the Host - Under normal circumstances, lactate metabolism in 
muscle is coupled to gluconeogenesis in the liver as lactate is shunted to the liver and 
converted to pyruvate and then to glucose.  The presence of tumor in the host, much 
like an active muscle, causes increased Cori cycling in the host.  However, in this case 
unless some sort of compensation occurs, this Cori cycling will reduce the amount of 
glucose available and/or increase the amount of energy required for gluconeogenesis.  
The end result of this process is cancer cachexia and death (Dills, 1993) The drug 
hydrazine sulfate is an inhibitor of gluconeogenesis from lactate and amino acids; it has 
shown some promise as a drug to treat cachexic cancer patients (Argiles and Lopez-
Soriano, 1998) (Figure 6).  
 
 
Figure 6: The Cori cycle. Tumor cells can be viewed as a replacement of or an 
addition to the active muscles in this figure. (web.indstate.edu/thcme/mwking/cori.gif) 
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The Tumor Metabolic Phenotype - As previously discussed, it has been well 
established that malignant tumor cells aerobically metabolize glucose into lactic acid 
(the Warburg effect) whether or not there is oxygen in adequate supply (loss of the 
Pasteur effect).  Increased rates of glucose uptake in tumor cells have been shown 
through fdG PET studies, and the rate of glycolysis in cultured mammalian tumor cells 
has been positively correlated to tumor aggressiveness.  Despite the fact that the 
Warburg effect appears (on the surface) to be detrimental to tumor cells, it is currently 
believed that this metabolic mutation confers a significant survival advantage to 
malignant cells (Gatenby and Gillies, 2004). 
 
 
At first glance, the glycolytic phenotype appears to place the malignant tumor cell 
at a metabolic disadvantage.  Only 2 net ATP are produced from the formation of lactate 
from pyruvate (whereas oxidative phosphorylation yields 38 net ATP).  The metabolic 
Figure 7: Tumor cells grow away from the basement membrane (i.e. away from their 
blood supply) and thus the ability for tumor cells to function metabolically whether 
oxygen is present or not confers upon those tumor cells a considerable evolutionary 
advantage over their host (Gatenby and Gillies 2004). 
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products of glycolysis result in a consistent acidification of the extracellular space, 
perhaps leading to cellular toxicity.  So, why and how would these seemingly lethal 
disadvantages confer an evolutionary advantage to malignant cells? (Figure 7). 
Pre-malignant lesions appear to be very well vascularized only in a macroscopic 
sense.  When examined more closely, it is apparent that although a tumor may appear 
to have a very vascular stroma, the pre-malignant cell mass is separated from the blood 
vessels by a basement membrane.  Oxygen tensions have been measured in situ in 
human malignant tumors.  Cells adjacent to capillaries displayed a mean O2 
concentration of 2%, and cells located 200 micrometers from the nearest capillary 
displayed a mean O2 concentration of 0.2% (Dang and Semenza, 1999).  Assuming that 
this basement membrane stays intact, and understanding that there are finite limits to 
oxygen and glucose diffusion from the stromal capillaries through the basement 
membrane into the tumor, it is obvious that early carcinogenesis and development of 
the malignant phenotype actually occur in an avascular environment (Gatenby and 
Gillies, 2004).  As proliferation continues pushing cells away from the basement 
membrane, pre-malignant lesions will develop an area of hypoxia at and outside of the 
oxygen diffusion limit.  It is at this point where nature will favor cell phenotypes that are 
adapted to harsh environments with low substrate availability.   
Normal cells respond to hypoxia by induction of the hypoxia inducible 
transcription factor HIF-1, a basic-helix-loop-helix (bHLH) factor that contains 2 subunits 
(HIF-1 alpha and HIF-1 beta).  HIF-1 beta is also known as the arylhydrocarbon 
receptor nuclear translocator (ARNT). HIF-1 binds to the DNA sequence 5’-RCGTG-3’ 
and increases the expression of glycolytic enzyme genes such as aldolase A, enolase 
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1, lactate dehydrogenase A, PFK, phosphoglycerate kinase, and pyruvate kinase M as 
well as the VEGF gene.  Glycolytic enzyme gene regulation is also controlled at the 
carbohydrate response element (ChoRE; 5’-CACGTG-3’).  The HLH-leucine zipper 
transcription factor USF2 binds at this site and also up-regulates the glycolytic genes 
(Dang and Semenza, 1999).  It is also interesting to mention that apoptotic signals 
brought on by genotoxic exposure tend to have the opposite effect on glycolytic genes.  
That is, genotoxic exposure (DNA damage by cisplatin, etoposide, or gamma-
irradiation) down-regulates key glycolytic enzyme genes (HK, PFK-1, and PK, among 
others) (Zhou et al., 2002). 
Lactic Acid Metabolism in Astrocytomas - So far, we have established that malignant 
tumor cells preferentially undergo “aerobic glycolysis”, i.e. when presented with glucose 
as a substrate tumor cells rapidly metabolize it into lactate regardless of the state of 
oxygenation of the cell.  We have also discussed the loss of the Pasteur effect 
(inhibition of glycolysis in the face of adequate oxygen content) and gain of the Crabtree 
effect in tumor cell glycolysis (glycolysis proceeds independent of oxygen content and 
cannot be regulated).  As described, this metabolic pathway is certainly a large part of 
the unique tumor metabolic phenotype (although not the only part) and therefore has 
served as a therapeutic target for many cancer researchers.  However, there has been 
new research into the nuances of lactate metabolism that may serve to reverse many of 
the preconceived notions of lactate’s role in the cell. 
For many years lactate has been considered a useless end product of anaerobic 
energy metabolism, and if allowed to accumulate, could become harmful. Recent 
research, however, has shown that lactate actually plays a transient, yet major role in 
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aerobic energy metabolism in the normal brain (Schurr, 2006).  Central to this notion is 
a hypothesis by Magistretti and colleagues known as the astrocyte-neuron lactate 
shuttle hypothesis (ANLSH).  Normal astrocytes were found to respond to neuronal 
activity mediated by the neurotransmitter glutamate by increasing glucose consumption 
and producing more lactate. In parallel, neurons preferentially oxidize lactate present in 
the extracellular space rather than glucose to meet their energy demands (Pellerin and 
Magistretti, 2004).  Supporting this hypothesis is a functional imaging study using two 
photon spectroscopy demonstrating spatiotemporal partitioning of glycolytic and 
oxidative metabolism between astrocytes and neurons during focal neuronal activity, 
establishing a unifying hypothesis for neurometabolic coupling between early oxidative 
metabolism in neurons and late activation of the ANLS (Kasischke et al., 2004) (Figure 
8).  
 
 
Figure 8: The astrocyte-neuron lactate shuttle hypothesis (ANLSH).  Normal astrocytes,
in a supporting role for surrounding neurons, will take in glucose and metabolize it to
lactate, which is then shunted out of the astrocytes and taken up by the surrounding
neurons.  This lactate then enters the TCA cycle of neurons in their mitochondria where
NADH is oxidized to generate ATP (Pellerin and Magistretti 2004). 
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Many studies have shown that glutamate uptake stimulates astrocytes to 
produce and secrete lactate to feed neurons in vitro and in vivo.  Kasischke and 
colleagues used two-photon fluorescent spectroscopy and confocal microscopy to 
examine NADH concentration (a signature of glycolysis or oxidative phosphorylation) in 
the CA1 region of the rat hippocampus through stimulation of the Schaffer collateral 
pathway.  At low magnification of the confocal microscope the tissue presented a 
biphasic response: an initial “dip” in the NADH level followed by an “overshoot”.  Upon 
closer confocal magnification it was observed that the “dip” in the fluorescent signal and 
return to baseline was restricted to the dendrites of neurons in a small area of the 
hippocampus.  Since this signal originated from the mitochondria, this data was 
interpreted as a burst in oxidative phosphorylation (and NADH consumption) followed 
by activation of the TCA cycle to regenerate NADH.  The late “overshoot” fluorescent 
signal was located in the cytoplasm of the processes of astrocytes.  This signal was 
interpreted as a burst in glycolysis in which large amounts of cytoplasmic NADH is 
generated before being converted back to NAD+ as lactate is produced (Kasischke et 
al., 2004; Pellerin and Magistretti, 2004).  These metabolic processes are separated 
temporally, spatially, and pharmacologically (the oxidative response in neuronal 
dendrites could be inhibited by AMPA/kainate receptor activation whereas the glycolytic 
response in astrocytes could not, indicating that the former was a postsynaptic 
response and the latter was presynaptically triggered).  These findings strongly support 
the theory of the ANLSH and some researchers have gone so far as to hypothesize that 
it is lactate and not pyruvate that is the end product of cerebral glycolysis and that 
lactate is the central fuel that feeds into the citric acid cycle (Schurr, 2006).  Other 13C 
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and 1H studies demonstrated two metabolic pools of lactate and pyruvate, and that 
exogenous lactate was the major substrate for oxidative metabolism of glioma cells and 
the other pool was related to aerobic glycolysis (Bouzier et al., 1998).  Whether or not 
these hypotheses are indeed correct, there is undeniable evidence that shows 
production of significant amounts of lactate in tumor cells.  Glioma cells have a very 
efficient method of removing excess lactate (not used in metabolism) from the 
cytoplasm in order to keep intracellular pH at a working level. 
Monocarboxylate Transport 
Lactate was once thought to be removed from cells via simple diffusion through 
the membrane.  Recent studies, however, have identified a family of monocarboxylate 
transporters (MCTs) that facilitate the passive transport of lactate across the plasma 
membrane.  These transporters work as symporters, effluxing lactate with H+ for 
example.  There are at least 14 members of the MCT family found in the human 
genome (the so-called SLC16 gene family), however only 4 of these (MCT 1-4) appear 
to be functional (Halestrap and Price, 1999).  These MCTs transport lactate and H+ out 
of the cytosol, thus leading to an increase in intracellular pH. However, these are not the 
only means by which tumor cells may regulate pH (Mathupala et al., 2007).  
Transmembrane studies have shown that tumors may use gradients such as sodium to 
exchange H+ via the sodium-hydrogen ion exchanger (Gillies et al., 1990) or the Na+ 
dependent Cl-/HCO3- exchanger (Lee and Tannock, 1998).  These cells were shown to 
be at or even above normal physiologic pH.  This has been confirmed in 31P Magnetic 
Resonance Spectroscopy (MRS) studies of in situ tumor cells (Stubbs et al., 1999). 
In order for MCTs to serve as viable targets for clinical therapeutics in malignant 
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tumors, they must differ significantly from wild type MCTs in level of expression, isotype 
expression, or both.  MCTs 1 and 2 are highly expressed in malignant glioma 
(Mathupala et al., 2004) whereas MCT 3 (formerly known as type 4) predominates in 
normal brain.  The function of MCTs can be disrupted by 1) small molecule inhibitors 
such as cinnamic acid derivatives, 2) by targeting their expression with post 
transcriptional gene-silencing strategies, or 3) by targeting accessory membrane 
proteins like gp70 and CD147 (Mathupala et al., 2007).  In human cultured glioblastoma 
cells, the small molecule MCT inhibitor alpha-cyano-4-hydroxy-cinammic acid (ACCA) 
was successful in increasing intracellular lactate in tumor cells, shrinking tumor bulk, 
and upon exposure to low dose radiation caused rapid morphological changes in the 
tumor cells that led to apoptotic cell death (Colen et al., 2006).  Through post-
transcriptional gene silencing techniques, MCT 1 and 2 down regulation led to a 
decrease in efflux of lactate in tumor cells by 85% and significant necrosis in the tumor, 
however it only led to a pH reduction by 0.6 units (Mathupala et al., 2004).  This result is 
likely explained by the aforementioned additional regulators of intracellular pH. Similar 
findings were obtained using the MCT inhibitor quercetin in rat C6 glioma cells (Volk et 
al., 1997). 
Preliminary Data 
MCT2 Proximal Promoter Harbors cis-elements that Respond to Glycolytic 
Metabolism and Erythopoietic Signaling - As part of ongoing research in the 
Prinicpal Investigator's laboratory, a gene-library clone search on human genome data 
linked to clone archives of the Human Genome Project via the National Center for 
Biotechnology Information (NCBI) server in 2004, to locate a clone harboring the 
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monocarboxylate transporter-2 (MCT2) gene.  A Fosmid clone (pFOS) was located 
which straddled the chromosomal location (chromosome location 12q14.1) for MCT2 
gene.  The clone was obtained and Fosmid DNA isolated, digested with restriction 
enzymes.  Based on in silico mappings of the chromosomal region, a BamH I fragment 
that harbored a 4.2 kbp region of the MCT2 proximal promoter and the first exon was 
identified, gel-purified and cloned into plasmid pUC18.  This was sequenced to verify 
identity of the sequence with information from in silico analysis.  
Once the BamH I clone was confirmed to contain the MCT2 promoter by 
sequencing, the 4.2 kbp MCT2 promoter was cloned into pGL2-luciferase reporter gene 
vector (Promega) (Figure 9). 
 
Figure 9: The upstream promoter for the monocarboxylate transporter 2 (MCT-2) gene. 
Several sequences upstream from the MCT-2 gene were found to be homologous to 
binding domains for many well-known regulatory proteins such as GATA-1, p53, c-myc, 
c-myb (all tumor suppressor proteins), AP-1 (part of the protein kinase C pathway), and 
CREB (Figure from Mathupala, NIH grant). Sequence map is displayed for the proximal 
1.6 kbp region of the MCT-2 promoter within the 4.2 kbp Bam H1 clone. Individual 
response elements identified by sequence analysis are indicated within the figure. 
Primary GBM Tissue and U-87MG Glioma Cells Express GATA-1 at High Levels - 
Based on our identification that multiple GATA-1 elements are present on the proximal 
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MCT2 promoter, a search of the currently available scientific literature was carried out, 
which indicated that expression of GATA-1 had not been reported, nor examined to 
date, either in experimental brain tumor cell lines or in primary brain tissues (normal or 
pathological).  Thus, we undertook the following studies in 1] U-87MG glioma cells, 2] in 
normal brain tissue, and 3] in primary GBM tissue.  Normal human brain tissues were 
obtained from autopsy specimens.  GBM tissue specimens that contained >90% tumor 
(from surgical specimens accrued through institutional approved clinical protocols; Dr. 
Andrew E. Sloan) were used in the study. 
Analysis of U-87MG Glioma Cell Line for Expression of GATA-1 - U-87MG cells 
growing under exponential culture conditions were washed in cold PBS and lysed in situ 
using a lysis buffer consisting of 50 mM sodium phosphate, pH 7.5, 10 mM Glucose, 10 
mM 1-thioglycerol, 0.1% Triton X-100, 1% NP-40, supplemented with a protease 
inhibitor mix (Roche Molecular Biochemicals, Indianapolis, IN).  Protein concentrations 
of diluted homogenates were assayed by the Bradford method and 5 to 20 Pg of total 
protein were resolved by SDS-PAGE (10%) (Figure 10).  Thus, U-87MG glioma cells 
(which show a high glycolytic phenotype) express GATA-1 (~ 47 kDa), and is a suitable 
experimental model for both in vitro and in vivo studies described below. 
MW   1      2   3 4      1       2      3       4 
A B
97kDa
66kDa
45kDa GATA-1
 
Figure 10: Lane 1,5 mg; lane 2, 10 mg; Lane 3, 15 mg; Lane 4, 20 mg total protein 
respectively. Panel A: SDS-PAGE profile; Panel B: Western blot using GATA-1 
polyclonal antibody (Novus Biologicals). 
 
 
  
33
Analysis of Normal and GBM Brain Tissue for Expression of GATA-1 - As 
described above two normal brain tissue specimens and three GBM tissues were 
examined by western analysis for the presence, and expression levels of GATA-1.  In 
brief, frozen tissue were sectioned into 0.5 mm slices, washed x3 in ice-cold PBS to 
remove residual blood (presence of which may give false-positive readings) and 
homogenized in the lys is buffer described above.  25 Pg aliquots of total protein were 
resolved by SDS-PAGE (10%) and expression of GATA-1 analyzed by western blotting 
(Figure 11).  
Thus, GBM tissue express GATA-1 at much higher levels in comparison to that 
for normal brain tissues, which minimally express the transcription factor.  
1 2        3 4        5 1 2       3       4    5
A B GATA-1
 
The data presented above provides GATA-1 protein expression patterns in 
normal and malignant brain tissues, as well as in one established experimental brain 
tumor cell-line we plan to use during our investigations. Normal or malignant brain 
tissues have not been examined for their GATA-1 status in literature to date. Thus, the 
data presented above in novel, and, with our previous evidence for the presence of 
GATA-1 cis-elements on the MCT2 promoter, provides additional proof that a GATA-1 
mediated signaling system may be present in malignant brain tumors to maintain a 
Figure 11: Panel A, SDS-PAGE; Panel B, Western blot for GATA-1. Lane 1, 
normal brain-surgical resection during decompression procedure, 25 Pg total 
protein; Lane 2, autopsy specimen (45 min post-mortem), 25 Pg total 
protein;Lanes 3-5, GBM tissue with >90% tissue incidence of tumor, 25 Pg total 
protein per lane 
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highly glycolytic phenotype.  
Our current interest in GATA-1 stems from the fact that GATA islands have been 
identified in the upstream promoter segment of the gene for MCT-2 (recall that MCT 
isoform 2 is highly expressed in glioblastoma cells).  It has been implied that 
downregulation of GATA-1 protein will result in decreased transcription of MCTs, thus 
leading to lactate buildup inside of the tumor cells and tumor death (in spite of other 
mechanisms for proton removal from the cytosol such as sodium-hydrogen 
exchangers).  The above data is part of my advisor’s NIH RO1 grant and is central to 
my specific aims.  Surprisingly, central to this new therapy is a protein that, in the 
normal state, regulates the production of millions of perfectly normal red blood cells. 
GATA Family of Transcription Factors 
GATA-1 and Erythropoietin - The maturation of immature red blood cell precursors 
(proerythroblasts) into mature erythrocytes is normally under the control of a 
polypeptide hormone called erythropoietin (EPO), which promotes proliferation and 
survival of erythroid precursors (Orkin and Weiss, 1999).  When an erythropoietin 
molecule binds the erythropoietin cell surface receptor on erythroblasts, it induces 
and/or stabilizes an anti-apoptotic protein called bcl-x.  When researchers studied 
down-regulation of red blood cells more closely (through the use of caspases and cell 
surface death receptors on proerythroblasts on culture), researchers found that either 
deprivation of erythropoietin or activation of cell surface death receptors (i.e. Fas and 
Fas ligand, FasL) on erythroid cells leads to caspase-induced cleavage of a nuclear 
transcription factor called GATA-1.  This molecule has been found to be crucial for 
erythroblast maturation and survival (Orkin and Weiss, 1999).  GATA-1 is abundant in 
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erythroid precursors, and also has been found to strongly induce expression of bcl-x 
(cooperating with EPO).  
The GATA family consists of 6 transcription factors (GATA-1 through GATA-6). 
All of these proteins bind the DNA consensus sequence (A/T)GATA(A/G) via 2 
characteristic C4 zinc finger motifs (Cys-X2-Cys-X17-Cys-X2-Cys) (Ferreira et al., 2005).  
GATA-1 was first identified as a protein with binding specificity to Beta-globin 3’ 
enhancer and the gene for GATA-1 is localized to Xp21-11.  GATA-1 is essential for 
normal erythropoiesis and GATA-1 deficient mice are unable to produce mature 
erythrocytes.  GATA-1 also plays a role in megakaryocyte regulation and eosinophil 
development.  It has been implied that GATA-1 is directly involved in cell survival 
through its activation of EpoR erythropoietin receptor and its known target gene Bcl-XL 
(an anti-apoptotic protein).  A variety of GATA-1 target genes have also been 
hypothesized to be involved in cell cycle regulation and/or proliferation and 
differentiation processes.(Ferreira et al., 2005). 
 
Figure 12: The DNA binding domain of the GATA-1 molecule contains a novel structure 
that resembles cys-cys variety zinc finger domains. 
(gibk26.bse.kyutech.ac.jp/jouhou/image/dna-protein/all/small_N1gat.png) 
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Short DNA sequences within control elements of genes constitute cis-regulatory 
motifs recognized by nuclear proteins that participate in transcription.  Through studies 
of hematopoietic stem cells, GATA-1 became a well known cis-acting regulatory 
element in several other gene promoters besides those that control hematopoiesis, for 
example platelet factor 4, mast cell carboxypeptidase A (MC-CPA), preproendothelin-1, 
and vascular cell adhesion molecule-1 (VCAM-1) (Orkin, 1992).  GATA motifs upstream 
of genes have various roles, but predominately these sequences (when bound to 
GATA-1) act as upstream promoters, enhancers, and locus control regions (LCRs).  
The individual GATA sequences may vary, and may be present in varying degrees of 
complexity. 
Members of the GATA-binding protein family are related by a highly conserved 
protein domain necessary and sufficient for DNA-recognition.  The DNA-binding domain 
is characterized by a novel structure: 2 homologous finger domains that resemble cys-
cys zinc fingers (Orkin, 1992; Tang et al., 2001) (Figure 12).  These domains are very 
highly conserved among mammals, avians, and amphibians.  There so far have been 
roughly 8 different GATA binding proteins (defined as GATA-1 through GATA-8), but the 
most well known are GATA-1 through GATA-4.  GATA-1 has also been called “the 
erythroid transcription factor”, as it is hematopoietic specific and abundant in erythroid, 
megakaryocytic, and mast cell lineages (Orkin, 1992).  Because GATA-1 has been also 
identified in pluripotent mouse and human cell lines, it is thought to be expressed in 
mutipotential progenitor cells and expression maintained thereafter.  GATA-2 and 
GATA-3 are found in megakaryocytes, T-cells, and mast cells, while GATA-4 enjoys 
very little tissue expression. 
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Project Outline and Hypothesis 
There are many unique features of tumor cells (Glioblastoma, in particular) that 
represent potential targets for gene therapy.  The main thrust of my research proposal is 
to target one of these unique features, namely the monocarboxylate transporter, using a 
novel method of translational regulation.  Glioblastoma cells purposefully modify their 
own biochemistry to undergo “aerobic glycolysis” and lactic acid fermentation even in 
the presence of ample oxygen.  The excess lactic acid produced by the tumor cells is 
rapidly shunted out of the tumor cell cytosol by the aforementioned cell membrane 
transporters, creating a toxic acidic microenvironment favoring tumor invasion as well as 
an acceptable intracellular pH allowing basic enzymatic function to continue.  Down-
regulation of this transporter (using a variety of methods including the drug a-cyano-4-
hydroxycinnamic acid) has been shown to arrest and even retard the growth of 
Glioblastoma cells in vivo and in vitro.  It is my goal to block the transcription of lactate 
transporter isoform 2, which has been shown to be up-regulated in Glioblastoma cells.  I 
will accomplish this by using small interfering RNA (siRNA) against mRNA transcripts of 
GATA-1 protein, a recognized transcription factor for the promoter of lactate transporter 
isoform 2.  I will first demonstrate that siRNA against GATA-1 delivered to U87-MG 
Glioblastoma tumor cells in vitro via liposome transfection results in decreased GATA-1 
protein.  I will also simultaneously determine the anti-GATA-1 siRNA sequence most 
effective at producing this decrease.  Next I will use a retroviral vector to examine the 
efficiency of anti-GATA-1 siRNA induced GATA-1 transcription inhibition on cell growth, 
apoptosis, and metabolism (in particular, lactate metabolism) in vitro.  
The second phase of this project will attempt to test the opposite situation from 
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phase 1; that is, we will use a different set of plasmids to over-express GATA-1 in U-
87MG tumor cells and examine the effects this will have on proliferation of the tumor 
cells, the cell cycle, MCT-2 expression and gene transcription, and lactate efflux and 
metabolism. 
Experimental Methodology 
Small Interfering Ribonucleic Acids [siRNAs] and Gene Downregulation: Gene 
Transcription and Translation and Gene Silencing - Deoxyribonucleic Acid (DNA) is 
composed of a double helix of two long chains of covalently linked deoxyribonucleotides 
(adenine, guanine, cytosine, and thymidine).  The two DNA strands have 5’ and 3’ ends 
and normally are bound to each other (A to T and C to G).  The strands contain identical 
information (in normal circumstances, i.e. excluding mutations or translocations) but are 
linked together in opposite directions such that the sense strand is read from 3’ to 5’ and 
the antisense (or template strand) is bound to it from 5’ to 3’.  Gene transcription (the 
formation of messenger RNA from native DNA) takes place in the nucleus of the cell.  
Certain transcriptional enzymes unfold the chromosomal DNA and others (like RNA 
polymerase) separate the helix and read the template strand (only) from 5’ to 3’ and 
synthesize long single strands of messenger ribonucleic acid (mRNA).  Gene translation 
takes place in the rough endoplasmic reticulum (rER) of the cytoplasm.  Ribosomes 
(made up of ribosomal RNA or rRNA) recognize distinct 3-base pair long codons in the 
mRNA and match these up to complementary 3-base pair sequences on transfer RNA 
(tRNA) molecules that are linked to amino acids.  The Genetic Code determines which 
specific amino acids are linked to which specific codon (there is overlap and there also 
are specific start codons that signal the ribosome to begin translation and stop codons 
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that signal the ribosome to fall off of the mRNA strand). 
It stands to reason that if a researcher knows the specific sequence of base pairs 
of a gene or genes of interest, then he/she would be able to synthesize antisense RNA 
against that sequence (that is, a single strand of RNA that is complementary to the 
single strand mRNA copy of that gene).  When introduced into the cytosol, theoretically 
these sequences would (by Brownian motion) seek out their complementary mRNA 
sequence and bind to it, forming a double strand of mRNA and rendering it unreadable 
by the ribosomes (which can only translate single stranded mRNA into proteins).  In 
general, this method is very ineffective at down-regulating proteins, and a more specific 
method is needed to apply this principle in vivo. 
In their work on nematodes and the protein unc-22 (important for muscle 
function), Andrew Fire and Craig Mello (eventual Nobel prize winners in medicine) had 
witnessed the failure of single stranded antisense RNA against this protein, and had 
witnessed that it had appeared that sense RNA seemed to work similarly to antisense 
RNA.  They (correctly) predicted that it was actually double stranded RNA that was the 
culprit for the apparent initial success of antisense RNA.  They guessed (again, 
correctly) that previous preparations of “single stranded” antisense RNA was 
contaminated with a small amount of “sense” RNA which then annealed to its 
complement antisense RNA before re-introduction into the cytosol.  Sure enough, when 
double stranded sense and antisense RNA against the unc-22 gene was introduced into 
nematodes, uncontrollable twitching of the nematode ensued (evidence of muscle 
protein dystrophy by knockdown of unc-22).  The field of “RNA interference” was born 
(Lau and Bartel, 2003) (Figure 13).  The essence of this newly discovered host cell 
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machinery is as follows: small foreign pieces of double stranded RNA in the cytosol are 
recognized by the protein “DICER” and cleaved into small fragments (termed “small 
interfering RNAs”).  Single strands of these fragments then are loaded onto “RISC” 
proteins which then seek out RNA sequences that are homologous to the sequences to 
which they are attached.  If a RISC complex binds a homologous RNA sequence, it 
activates a host of cell machinery (including DICER and exonucleases) and degrades 
that RNA strand. 
 
Figure 13: Double stranded RNA is recognized by the cytosolic protein DICER as 
foreign and is cleaved into small interfering RNAs (siRNAs). These siRNAs bind RNA-
induces silencing complexes (RISC) molecules to form activated RISC complexes 
(RISC*). RISC is thought to have helicase and endonuclease activity (or may be 
associated with other enzymes). If a RISC complex encounters an mRNA sequence 
that is complementary to the sequence that it carries then that mRNA molecule is 
cleaved and degraded. This may be foreign mRNA (i.e. viral) or even native mRNA 
molecules.  
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Application of RNA Interference to Brain Tumor Research - RNAi induced by 
synthetic hairpin RNAs (shRNAs) has recently been used to study gene function in 
plants and animals and has been shown to silence genes in much the same way as 
siRNAs (Matzke and Matzke, 2003).  siRNAs are roughly 25 nucleotides long, and are 
complementary to both the sense and antisense strands of mRNA (suggesting a double 
stranded origin).  Evolutionarily, they may have had a role in silencing transposable 
elements, repetitive genes, or viruses (Novina and Sharp, 2004; Sharp, 1999). 
Once siRNA is in the cytosol, it binds to RNA-induced silencing complexes 
(RISC) to form activated RISC (RISC*). RISC* now is capable of binding an mRNA 
strand (single stranded) complementary to the siRNA that it carries in the cytosol and 
bringing about its degradation.  There is evidence that the 5’ end of the siRNA is the 
ruler for position of subsequent cleavage, and a 5’ phosphate is required on the target 
mRNA (Martinez et al., 2002).  In fact, the 5’ end of the siRNA fragment bound to RISC 
has been shown to be necessary and essential to RNAi activity (Chiu and Rana, 2002). 
This presents an exciting new application to brain tumor research.  SiRNA is 
nonselective, that is, it can trigger degradation of native mRNA transcripts as well as 
foreign ones.  Therefore, purposeful injection or introduction of siRNA molecules against 
a known mRNA sequence could very selectively knock down that protein in the cell 
(Ezzell, 2002).  There are essentially three potential sites for therapeutic intervention: 
transcriptional, post-transcriptional, and post-translational.  Most drugs target post-
translational molecules.  SiRNA has the ability to target peptides before they are even 
peptides i.e. target the mRNA that codes for them (Shuey et al., 2002).  A very clear 
target in the malignant tumor cell is the aforementioned lactate transporter.  Essential to 
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tumor cell survival and isoforms that are unique to glioblastoma, the lactate transporter 
offers an attractive target for post-transcriptional therapy. 
The selection and design of siRNA molecules is challenging. The keys to siRNA-
dependent gene silencing depend upon a number of critical factors: target sequence 
selection and siRNA design, suitable cell line or culture system, optimized delivery 
conditions, abundance and turnover rate of the target mRNA or protein of interest, and 
accuracy and ease of assaying for mRNA levels, protein levels, or phenotype.  We 
chose the Dharmacon SMARTpool siRNAs (Dharmacon, Inc.) which incorporate several 
features optimum for effective silencing: 21-nucleotide RNA oligonucleotides forming a 
19-base pair duplex core, symmetrical 2 nucleotide 3;-UU overhangs, 5’-phosphorylated 
antisense strand, desalted and quality controlled (average molecular weight = 13,300 
g/mole, confirmation of duplex formation by non-denaturing gel electrophoresis) (Figure 
14). 
 
Figure 14: Example of a small hairpin RNAs (shRNAs) generated from an 
oligonucleotide DNA sequence from the beta-actin gene. A hairpin loop is located 
between the sense and antisense sequences on each complimentary strand. The 
shRNA acts like siRNA molecules capable of carrying out gene-specific silencing. (from 
“Knockout Inducible RNAi Systems User Manual,” Clontech Laboratories, Inc., Mountain 
View, CA) 
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Inducible RNAi expression systems; (Tet-On, Tet-Off systems) - One of the most 
efficient methods of down-regulating a given protein’s production in laboratory cultured 
cells is to transform those cells using an inducible vector with the gene of interest.  We 
chose the tetracycline transactivator system (Clontech).  This system can be 
programmed to either turn production of our gene of interest (in our case, siRNA genes) 
on or off in the presence of tetracycline or doxycycline.  We chose the tet-on system 
and it works as follows: our gene of interest is spliced into a vector downstream (and 
controlled by) an inducible promoter.  This promoter is off at baseline as the activator 
cannot bind to the promoter without doxycycline.  As doxycycline is added to cell media, 
it binds the activator which then is allowed to bind the promoter and our gene of interest 
is synthesized (Figure 15). 
 
Figure 15: Schematic of gene regulation in the inducible tTS system. The suppressor 
tTS binds the tetO sequence in the TRE(mod) promoter region of the response plasmid, 
suppressing shRNA expression. In the presence of doxycycline or minocycline, the tTS 
dissociates from the TRE(mod) and allows activation of shRNA transcription from the 
downstream U6 promoter. [From the “Knockout Inducible RNAi Systems User Manual”, 
Clontech Laboratories, Inc.] 
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CHAPTER 2 
EFFECT OF DOWN-REGULATION OF GATA-1 AND EXPRESSION IN GLIOMA 
CELL LINE U87-MG 
Introduction 
From our prior work we know that there are GATA-1 regulatory islands in the 
proximal MCT-2 promoter (preliminary data from NIH grant5R01 CA116257 (NCI/NIH) 
Mathupala, S.P. Ph.D. (PI) Lactate Transport as a Therapeutic Target in Glioma).  From 
the same preliminary data, we also know that GATA-1 protein is overexpressed in 
GBMs (both in GBM cell lines and in human primary GBMs from surgical specimens).  
The logical question that presents itself from these data is the following: What role does 
GATA-1 play in tumor metabolism?  More precisely, what role does GATA-1 play in the 
regulation of MCT-2 protein in U87-MG tumor cells? 
In order to examine the role of GATA-1 more thoroughly, we used a relatively 
new technique taking advantage of host cell machinery to knock down GATA-1 nearly 
completely in tumor cells.  We began by using simple liposomes to deliver 4 distinct 
siRNA sets against GATA-1 to cultured U87-MG cells and measured the ensuing 
knockdown of GATA-1 via western blot analysis.  We then designed short hairpin RNA 
molecules (shRNA) based on the siRNA data.  We then engineered a Moloney Murine 
Leukemia Virions (MOMLV) to deliver shRNA-containing plasmids at high efficiency to 
cultured U87-MG cells, creating stable transformed cell lines that can produce shRNA 
against GATA-1 on our command via administration of doxycycline or minocycline.  
Through western blots we then looked at the effect of down regulation of GATA-1 on 
levels of MCT-2 protein in transformed U87-MG. 
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Design of siRNA, Theory, and Transfection Methods: The mRNA Sequencing of 
GATA-1 and Location of siRNA Targets 
In order to fully utilize the technology of siRNA mediated gene silencing, a few 
pieces of data are needed.  We need to know the sequence of the gene that we intend 
to target. We then need to select several different sequences within that gene that are 
relatively unique sequences (i.e. sequences that are unique to the gene of interest to 
avoid cross reaction of our siRNA with other mRNA transcripts).  We also need a non-
conserved sequence of mRNA that is not found in any known gene in the human 
genome (in this project we will be using human glioblastoma cells).  This will serve as a 
control sequence. Once we have selected these unique sequences we can then 
passively transfect these sequences into our cells of interest and test which sequence is 
most effective at knocking down the level of protein that we are targeting. In our case, 
that protein is GATA-1. 
The first step in the process involves a search on the NCBI website for the 
sequence of the GATA-1 protein.  This site can analyze the sequence for the consensus 
sequence for the given protein (i.e., there may be several different DNA sequences 
leading to GATA-1, this site helps us find the sequences that all of the variations have in 
common).  The end result of this is a cDNA sequence representing the GATA-1 gene. 
cDNA for human GATA-1 
1  gcaaaggcca aggccagcca ggacaccccc tgggatcaca ctgagcttgc cacatcccca 
61  aggcggccga accctccgca accaccagcc caggttaatc cccagaggct ccatggagtt 
121  ccctggcctg gggtccctgg ggacctcaga gcccctcccc cagtttgtgg atcctgctct 
181  ggtgtcctcc acaccagaat caggggtttt cttcccctct gggcctgagg gcttggatgc 
241  agcagcttcc tccactgccc cgagcacagc caccgctgca gctgcggcac tggcctacta 
   [siRNA#1 308-324] 
301  cagggacgct gaggcctaca gacactcccc agtctttcag gtgtacccat tgctcaactg 
361  tatggagggg atcccagggg gctcaccata tgccggctgg gcctacggca agacggggct 
421  ctaccctgcc tcaactgtgt gtcccacccg cgaggactct cctccccagg ccgtggaaga 
481  tctggatgga aaaggcagca ccagcttcct ggagactttg aagacagagc ggctgagccc 
541  agacctcctg accctgggac ctgcactgcc ttcatcactc cctgtcccca atagtgctta 
601  tgggggccct gacttttcca gtaccttctt ttctcccacc gggagccccc tcaattcagc 
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661 agcctattcc tctcccaagc ttcgtggaac tctccccctg cctccctgtg aggccaggga 
             [siRNA #3 768-786] 
721 gtgtgtgaac tgcggagcaa cagccactcc actgtggcgg agggacagga caggccacta 
781  cctatgcaac gcctgcggcc tctatcacaa gatgaatggg cagaacaggc ccctcatccg 
   [siRNA#2 843-861] 
841  gcccaagaag cgcctgattg tcagtaaacg ggcaggtact cagtgcacca actgccagac 
901  gaccaccacg acactgtggc ggagaaatgc cagtggggat cccgtgtgca atgcctgcgg 
961  cctctactac aagctacacc aggtgaaccg gccactgacc atgcggaagg atggtattca 
1021  gactcgaaac cgcaaggcat ctggaaaagg gaaaaagaaa cggggctcca gtctgggagg 
          [siRNA#4 1103-1122] 
1081  cacaggagca gccgaaggac cagctggtgg ctttatggtg gtggctgggg gcagcggtag 
1141  cgggaattgt ggggaggtgg cttcaggcct gacactgggc cccccaggta ctgcccatct 
1201  ctaccaaggc ctgggccctg tggtgctgtc agggcctgtt agccacctca tgcctttccc 
1261  tggaccccta ctgggctcac ccacgggctc cttccccaca ggccccatgc cccccaccac 
1321  cagcactact gtggtggctc cgctcagctc atgagggcac agagcatggc ctccagagga 
1381  ggggtggtgt ccttctcctc ttgtagccag aattctggac aacccaagtc tctgggcccc 
1441  aggcaccccc tggcttgaac cttcaaagct tttgtaaaat aaaaccacca aagtcctgaa 
1501  aaaaaaaaaa aaaaaaaaaa aa 
We then obtained 4 distinct pre-selected candidate siRNAs against GATA-1 
(Dharmacon RNA Technologies, siGENOME ON-TARGETplus set of 4 duplex LQ-
009610-00-0002 Human GATA1), these were arbitrarily defined as #1, #2, #3, and #4. 
These sequences are noted in red in the above sequence of the GATA-1 gene.  
#1 J-009610-06 
Sense Sequence  5'ACGCUGAGGCCUACAGACAUU 
Antisense Sequence       5’PUGUCUGUAGGCCUCAGCGUUU 
#2 J-009610-08 
Sense Sequence  5'CCAAGAAGCGCCUGAUUGUUU  
Antisense Sequence  5’PACAAUCAGGCGCUUCUUGGUU 
#3 J-009610-05 
Sense Sequence  5'GGACAGGCCACUACCUAUGUU 
Antisense Sequence  5’PCAUAGGUAGUGGCCUGUCCUU 
#4 J-009610-07 
Sense Sequence  5'GCUGGUGGCUUUAUGGUGGUU 
Antisense Sequence  5’PCCACCAUAAAGCCACCAGCUU 
We also obtained a control siRNA sequence that does not match any known 
gene sequence in GeneBank.  This sequence was designated as C. (Dharmacon RNA 
Technologies ON-TARGETplus siCONTROL Non-targeting siRNA). 
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C D-001810-01-05 
Sense Sequence  5’UGGUUUACAUGUCGACUAA 
Antisense Sequence  3’ACCAAAUGUACAGCUGAUU 
Transient Transfection of Dharmacon siRNA into U87-MG 
The U87-MG cell line is a cultured human glioblastoma/astrocytoma cell line 
obtained from ATCC (ATCC number HTB-14).  This cell line was chosen because it 
grows very nicely in cell culture and is tumorigenic when stereotactically injected into 
nude mouse or rat brain.  We created a 24-well plate with cultured U87-MG cells plated 
at a density of 100,000 cells per well at the start of transfection.  Our cultured cells grew 
in DMEM-F12 media with 10% fetal bovine serum, 1% L-glutamine, 1% 
penicillin/streptomycin, and 14 millimolar sodium bicarbonate, pH = 7.5.  Our cells 
incubated at 5% CO2 and 37o C. 
We then prepared our stock solutions of siRNA using 5x siRNA buffer to a final 
concentration of 20 µM.  We used a siRNA transfection kit (Ambion Silencer siRNA 
Transfection Kit, catalog # 1630 siPORT amine) to transfect our U87-MG cells (via 
liposome mediated transfection) with either #1, #2, #3, #4, or C siRNA.  After incubation 
we created cell lysates by adding 1 cc of lysis buffer (50 mM pH 7.5 sodium phosphate, 
10 mM, 10 mM 1-thioglycerol, 0.1% Triton X-100, and 1% NP-40) to our washed cell 
culture plates, scraping off the cells adherent to the plates, and homogenizing through 
pipetting.  After this we quantified the protein in our lysates using the Bradford assay for 
protein concentration (absorbance at 595 nanometers).  10 µl of our cell lysates were 
combined with 990 µl of water, creating a 100-fold dilution. 400 µl of this dilution were 
then combined with 0.4 cc of water and 0.2 cc of Bradford coomassie blue dye 
(Bradford, 1976).  We then ran the lysates on an SDS-polyacrylamide gel (10%) at 20 
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µg of protein/lane using the Bio-Rad mini-protean system.  This gel was then 
equilibrated in 25 ml 1X CAPS buffer (10 mM CAPS, pH = 11 with 10% methanol) with 
10% methanol and transferred onto a PVDF membrane at 100 V/1 hour. The membrane 
was then allowed to air dry, then wet with 100% methanol and then equilibrated in TBST 
(TBS-Tween: 10 mM Tris, Ph = 7.5; 150 mM NaCl; 0.05% Tween-20) for 5 minutes.  We 
then blocked the membrane for 1 hour in TBST + 5% milk.  A western blot was then 
performed to assay GATA-1 concentration using our antibody against GATA-1 (Santa 
Cruz Biotechnology, Inc. GATA-1 (H200): sc-13053) and a chemiluminescent 
secondary antibody (HRP-conjugated) against the primary antibody.  
After chemiluminescence and development, encouraging results were obtained. 
Western blots obtained here showed the knockdown of GATA-1 protein very nicely.  
Upon further analysis we determined that #4 was the most efficient siRNA against 
GATA-1.  After this experiment we utilized “quantum dots,” specialized our PVDF 
membranes in preparation for quantum dot blots.  For this method, we washed our 
membrane 4 times after transfer (in CAPS buffer, water, methanol, and then water 
molecules bound to secondary antibodies that give off light when stimulated by certain 
wavelengths (Figure 19).  There were significant differences in the way we developed 
again.)  The biotinylated molecular weight marker strip was cut from the main blot and 
developed separately.  The membranes were then washed in TBST and then blocked 
for1 hour in 100% fish serum. Our primary antibody was then added to the blots (16 µl 
of primary antibody + 16 ml TBST with 25% fish serum for the main blot) and incubated 
for 1 hour and then washed twice in TBST with 25% fish serum followed by our 
secondary antibody (16 µl secondary antibody in 8 cc TBST/25% fish serum for primary 
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blot).  We then concluded that siRNA sequence #4 is the most effective down-regulator 
of GATA-1 transcription in U87-MG cells (Figure 16).  This was to serve as our 
sequence of choice for the next step in the experiments: to engineer an inducible glioma 
cell line able to produce siRNA against GATA-1 upon our command. 
 
 
Figure 16: Representative Coomassie blue stain of SDS-PAGE gel (A) and western 
blot (B) against GATA-1 protein in U87-MG cells transfected with siRNA against GATA-
1 mRNA transcripts: The knockdown levels of GATA-1 indicate that siRNA #4 is the 
most effective sequence at silencing GATA-1 protein expression. Averaged data from 
three independent experiments are shown; Average drop in GATA-1 expression = 62% 
± 21.6; p = 0.008. Data analysis was done in collaboration with Michael Monterey and 
Dr. Mathupala. The pixel density of western blots were calculated with Un-Scan-It 
digitizing software (Silk Scientific, Orem, UT). Data were tabulated with SigmaPlot 8.0 
software (SPSS Inc., Chicago, IL). Band of interest; protein band used to normalize total 
protein in each lane. The Control was arbitrarily adjusted to 100% expression. 
 
Long-Term Regulated Silencing of GATA-1: Tet-on/Tet-off System 
Transfection of U87-MG cells with mobile genetic elements such as plasmids is 
much more efficient if a virus is used as a vehicle (i.e. transformation) rather than a 
  
50
liposome.  The next phase in our research involved engineering a virus in order to 
create a double stable tetracycline U87-MG tumor cell line containing 2 plasmids: A 
regulatory plasmid that produces a transcriptional activator in the presence of 
tetracycline (or doxycycline) and a response plasmid that responds to that 
transcriptional activating factor and produces siRNA against GATA-1. Both of these 
plasmids are available from various companies, and all plasmids are not created the 
same.  The response plasmid is made as a circular piece of DNA containing several 
genes of interest to the researcher.  These genes may include, among other things: 
Antibiotic resistance genes for cell selection after transfection or transformation, viral 
packaging genes for production of infectious virus to initiate transformation, a multiple 
cloning site (MCS) with specific restriction sites that the researcher may use enzymes to 
cut and insert a gene of interest into, and various promoters that control the genes on 
the plasmid (Figure 17). 
 
Figure 17: Schematic of gene regulation in the inducible tTS system. The suppressor 
tTS binds the tetO sequence in the TRE(mod) promoter region of the response plasmid, 
suppressing shRNA expression. In the presence of doxycycline or minocycline, the tTS 
dissociates from the TRE(mod) and allows activation of shRNA transcription from the 
downstream U6 promoter. [From the “Knockout Inducible RNAi Systems User Manual”, 
Clontech Laboratories, Inc.] 
  
51
 
 
Figure 18: pQC-tTS-IN regulatory plasmid and RNAi-Ready pSIREN-RetroQ-TetH 
Response Vector (Clontech, PT3811-5, cat # 630925). The regulatory plasmid has a 
strong promoter (Pcmv IE) and ampicillin, G418 resistance genes. The response 
plasmid is roughly 1 kilobase smaller than our first response plasmid.  It has no cGFP 
gene, so it must be selected for by the hygromycin resistance gene.  
Our first step was to select a regulatory and response plasmid system, and we 
chose the BD Tet-on system (Figure 18). This vector’s MCS had specific restriction 
sites, so we had to design forward and reverse sequence primers (oligonucleotides) for 
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GATA-1 siRNA and a forward sequencing primer specific for the cassette restriction 
sites. 
PRIMER SET FOR CONTROL [CLONTECH] 
FORWARD PRIMER 
5’GAT-CCG-TTA-GTC-GAC-ATG-TAA-ACC-ATT-GAT-ATC-CGT-GGT-TTA-CAT-GTC-
GAC-TAA-TTT-TTT-CCA-AG 3’ 
REVERSE PRIMER 
5’AAT-TCT-TGG-AAA-AAA-TTA-GTC-GAC-ATG-TAA-ACC-ACG-GAT-ATC-AAT-GGT-
TTA-CAT-GTC-GAC-TAA-CG 3’ 
PRIMER SET FOR SIRNA TEMPLATE #4 [CLONTECH] 
FORWARD PRIMER 
5’GAT-CCG-CCA-CCA-TAA-AGC-CAC-CAG-CTT-GAT-ATC-CGG-CTG-GTG-GCT-TTA-
TGG-TGG-TTT-TTT-CCA-AG 3’ 
REVERSE PRIMER 
5’AAT-TCT-TGG-AAA-AAA-CCA-CCA-TAA-AGC-CAC-CAG-CCG-GAT-ATC-AAG-CTG-
GTG-GCT-TTA-TGG-TGG-CG 3’ 
U6 FORWARD SEQUENCING PRIMER 
5’CTT-GAA-CCT-CCT-CGT-TCG-ACC-CCG-CCT-C 3’ 
We were then able to locate in this long sequence the area in which the siRNA 
#4 against GATA-1 is directed. Using this information, we then were able to design our 
control and test inserts (oligonucleotide sequences) to place into our plasmids.  Since 
we knew the restriction sites on the plasmid (Eco R1 and Bam H1) we were then able to 
design our primers (Integrated DNA Technologies).  Once we received the single 
stranded control and test primers, we set up an annealing reaction to ligate the 
complementary strands together to form our cassettes.  The primers were designed to 
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have overhanging ends that matched up with the restriction sites in the MCS.  The 
cassettes do not ligate end-to-end with each other because the 5’ ends are not 
phosphorylated (Figure 19). 
 
 
Figure 19: 0.8% Agarose DNA gel demonstrating our plasmids in their native, uncut 
state. The doublet represents the nicked and supercoiled states of the plasmids.  
Doublets representative of e.coli SURE. Lane MW = molecular weight marker 
 
After application of specific restriction enzymes to the response plasmid, the 
plasmid is now opened at the MCS and is linear.  Addition of our double stranded oligos 
initiated an annealing reaction and the plasmids now took up our cassettes into their 
MCS.  We then placed our newly annealed plasmids (with our siRNA gene insert) into 
E.coli SURE cells by electroporation.  These E. coli cells were then grown on ampicillin 
media (bacteria that have the plasmid are now ampicillin resistant, due to the gene on 
the plasmid).  Once the plasmid has amplified in E. coli sufficiently, we used a Qiagen 
kit (Qiaprep) to isolate the plasmids from the e. coli cells. 3 ml of our overnight e.coli 
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cultures were spun down at 10,000 rpm x 2 minutes (1.5 cc per 1 minute, removing 
supernatant in between spins).  We then added 150 µl of cold buffer P1 with RNAse, 
resuspending the pellet.  We then added 250 µl of buffer P2, then 350 µl of buffer N3 
followed by centrifugation at 13,000 rpm at 4o C for 10 minutes.  The supernatant was 
then recovered and centrifuged in a QIAprep spin column at 10,000 rpm for 30 seconds, 
followed by Buffers PB, PE, and EB with centrifugation between each steps.  This 
sample was quantified in a spectrophotometer (260 nanometers) and run on an agarose 
gel.  Afterwards, our plasmid was sent for DNA sequencing, which confirmed that in at 
least 1 set of plasmids, our cassette had been inserted.  We then proceeded to place 
our plasmids into packaging cells (eukaryotic PA317 cells) via transfection.  The goal of 
this step is to allow the plasmid to begin making virus, as our packaging cells are 
specially engineered to have the other half of the viral genome that is found on our 
response plasmid.  
72 hours after transfection the culture supernatant was recovered from the 
culture tubes, centrifuged at 5000G for 5 minutes to sediment cell debris.  Then 200 µl 
of supernatant was used on U87-MG cells permanently transfected with tTS in a 60 mm 
plate with 5 ml of DMEM medium (Polybrene was used to enhance transduction 
efficiency).  24 hours post transduction, the cells were selected in hygromycin and then 
trypsinized, plated onto a large 100 mm diameter plate and allowed to grow for 2 weeks 
until clonal cell populations appeared.  Single clones were isolated using cloning 
cylinders (agarose based anchoring method)(Mathupala and Sloan, 2009).  Then 6 
individual clones were placed in individual wells in a 6 well plate (x µg/ml) doxyxycline 
and incubated for 2 days.  A western blot was performed to determine the optimum 
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concentration of doxy required for GATA-1 knockdown. 
SDS-PAGE and Western Blot for GATA-1 after Doxycycline and Minocycline 
Mediated Induction 
Now that we have established our permanent transformed inducible U87-MG cell 
line and verified that both our response and regulatory plasmids have incorporated into 
the cell genome, we set up an induction experiment to verify that doxycycline and/or 
minocycline induces siRNA against GATA-1 transcripts and knocks down the level of 
this protein in our cells (and also to determine the optimum concentration of both drugs 
needed to achieve this). 
We began by growing our transformed U87-MG cells in 6 well plates in DMEM 
without antibiotics.  Stocks of doxycycline and minocycline (Sigma) were made at 1 
mg/ml and pH = 7.4.  We then added doxycycline and minocycline separately to two 
separate cultures in 6-well plates to create an increasing concentration of doxycycline 
and minocycline in each well as follows (in micrograms of drug/ml media): well 1 = 0, 
well 2 = 0.001, well 3 = 0.01, well 4 = 0.1, well 5 = 1, and well 6 = 10.  The plate was 
incubated for 2 days and the cells were then washed with PBS, trypsinized, and made 
into cell lysates.  We ran a western blot on these lysates with our primary anti-GATA-1 
antibody, and our results demonstrated a significant knockdown of GATA-1 protein in 
the cells exposed to 10 µg/ml of doxycycline and minocycline.  We then repeated the 
experiment using a different, stronger serial dilution of doxycycline and minocycline (in 
µg of drug/ml media): well 1 = 0, well 2 = 2.5, well 3 = 5, well 4 = 7.5, well 5 = 10, and 
well 6 = 20.  In both the minocycline and doxycycline experiments we saw a significant 
knockdown of GATA-1 in the 10 and 20 µg/ml wells (Figures 20, 21, 22, and 23)  
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Figure 20: Coomassie blue stain of SDS-PAGE gel (A) and Western blot using Qdot 
and anti-GATA-1 primary antibody (B).  Doxycycline induction of the response plasmid 
integrated into our U87-MG test cells with our siRNA #4 against GATA-1 indicated by 
concentration (0-10 µg doxycycline/µg media). Protein concentration is equal in all 
lanes. MW = molecular weight marker, BMW = biotinylated molecular weight marker. 
Band of interest; protein band used to normalize protein content across samples. 
 
 
Figure 21: Quantification of doxycycline induction of shRNA against GATA-1. 
Downregulation of GATA-1 by doxycycline induction of siRNA against GATA-1 is 
evident from the decreased protein concentration of GATA-1 at 10 micrograms per 
milliliter.  Averaged data from two independent experiments are shown; Average drop in 
GATA-1 expression = 73.5% ± 34.6; p = 0.095. Data analysis was done in collaboration 
with Michael Monterey and Dr. Mathupala. The pixel density of western blots were 
calculated with Un-Scan-It digitizing software (Silk Scientific, Orem, UT). Data were 
tabulated with SigmaPlot 8.0 software (SPSS Inc., Chicago, IL). Band of interest; 
protein band used to normalize total protein in each lane. The 0 Pg/ml sample was 
arbitrarily adjusted to 100% expression. 
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Figure 22:  Coomassie blue stain of SDS-PAGE gel (A) and Western blot using Qdot 
and anti-GATA-1 primary antibody (B).  Minocycline induction of the response plasmid 
integrated into our U87-MG test cells with our siRNA #4 against GATA-1 indicated by 
concentration (0-10 µg minocycline/µl media). Protein concentration is evidently 
identical in all of the lanes. MW = molecular weight marker, BMW = biotinylated 
molecular weight marker.  
 
Figure 23: Quantification of minocycline induction of shRNA against GATA-1. 
Downregulation of GATA-1 by minocycline induction of siRNA against GATA-1 is 
evident from the decreased protein concentration of GATA-1 at 10 micrograms per 
milliliter. Averaged data from two independent experiments are shown; Average drop in 
GATA-1 expression = 62.8% ± 8.06; p = 0.008. Data analysis was done in collaboration 
with Michael Monterey and Dr. Mathupala. The pixel density of western blots were 
calculated with Un-Scan-It digitizing software (Silk Scientific, Orem, UT). Data were 
tabulated with SigmaPlot 8.0 software (SPSS Inc., Chicago, IL). Band of interest; 
protein band used to normalize total protein in each lane. The 0 Pg/ml sample was was 
arbitrarily adjusted to 100% expression. 
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Western Blot Analysis of both GATA-1 and MCT-2: Decrease in Levels of MCT-2 
seen Concomitantly with Down-Regulation of GATA-1 
The next logical step in our examination of GATA-1 is to determine the effect of 
decreased levels of GATA-1 on levels of MCT-2 in transformed U87-MG glioblastoma 
cells.  If GATA-1 is responsible for upregulation of MCT-2 transcription and expression, 
then a decrease in levels of GATA-1 protein in our transformed tumor cells should lead 
to a decrease in levels of MCT-2 (although perhaps not in direct parallel). 
We began by selecting 4 control and 4 test insert clonal isolates.  Based on our 
induction data, we induced all 8 with 10 µg /ml doxycycline for 3 days.  We then made 
cell lysates from all of the cultures and quantitated the protein in the previously 
described manner.  We ran all 8 isolates on an SDS-PAGE gel at 20 µg of protein/lane 
and transferred it on to a PVDF membrane using our standard method previously 
described.  We then probed our membrane with our primary antibody against GATA-1, 
applied secondary quantum dot antibody, and imaged the blot.  We then re-probed the 
blot using our primary antibody against MCT-2 (Alpha Diagnostic International, Inc., San 
Antonio TX), re-exposed the membrane to our same quantum dot secondary antibody, 
and imaged the blot.  The nature of quantum dot technology allows our primary and 
secondary antibodies to give off signal for a much longer time than standard HRP-
mediated chemiluminescence allows, so multiple probes and images of the same blot 
are possible without loss of signal.  The specific bands on the image were scanned 
using densitometric software (Un-Scan-It, Silk Scientific, Orem, UT).  There are clearly 
changes in perceived levels of each protein due to background staining, and the 
quantitative data are presented as-is.  A coomassie blue stain was performed on the 
original gel and verified that equal protein was used in each lane (Figures 24, 25, 26). 
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Figure 24: Western blot of control (labeled “C”) and test (labeled “T”) clonal isolates 
double probed for GATA-1 protein and MCT-2 protein. GATA-1 runs at 47 kDa whereas 
MCT-2 runs from 35-40 kDa, (since it is a membrane protein it runs faster than its 
estimated true weight of 55 kDa). Coomassie blue stained gel confirmed equal protein 
in all lanes. 20 µg of protein were loaded in all lanes.  The upper panel indicated the 
same western blot first probed with antibody against GATA-1 only, to differentiate 
between the two proteins. 
 
Figure 25: Densitometric results of the GATA-1 band using Un-Scan-It (Silk Scientific, 
Orem UT). C (Gata) corresponds to Lanes C3A1, C3A2, C3A4, C3A5 in the western 
blot; T (Gata) corresponds to T3A2, T3C1, T3D1, T3D6. For statistical analysis, the four 
individual control or test samples were analyzed for total protein and GATA-1 protein 
levels.  Averaged data from each of the four individual control or test lanes are shown; 
Average drop in GATA-1 expression = 62.1% ± 6.74; p = 0.047.  Data analysis was 
done in collaboration with Michael Monterey and Dr. Mathupala. The pixel density of 
western blots were calculated with Un-Scan-It digitizing software (Silk Scientific, Orem, 
UT). Data were tabulated with SigmaPlot 8.0 software (SPSS Inc., Chicago, IL). Band of 
interest; protein band used to normalize total protein in each lane. 
 
GATA1 
MCT2 
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Figure 26: Densitometric results of the MCT-2 band using Un-Scan-It (Silk Scientific, 
Orem UT). The C (MCT2) and T (MCT2) correlate to the same respective lanes in the 
lowere western blot. For statistical analysis, the four individual control or test samples 
were analyzed for total protein and MCT2 protein levels.  Averaged data from each of 
the four individual control or test lanes are shown. Average drop in MCT2 expression = 
56.5% ± 30.2; p = 0.1175.  Data analysis was done in collaboration with Michael 
Monterey and Dr. Mathupala. The pixel density of western blots were calculated with 
Un-Scan-It digitizing software (Silk Scientific, Orem, UT). Data were tabulated with 
SigmaPlot 8.0 software (SPSS Inc., Chicago, IL). Band of interest; protein band used to 
normalize total protein in each lane. 
MTT Assay for Cell Proliferation 
To test for effects of GATA-1 silencing, the engineered U-87MG cells were plated 
in DMEM media lacking phenol-red, in 24-well plates at 0.3 x 10^6 cells per well.  Post 
72 hrs plating, the media were aspirated and fresh pre-warmed media containing MTT 
at 0.5 mg/ml, according to established protocols (Freshney, 2005).  The cells were 
incubated for 90 minutes in the tissue culture incubator until formazan formation was 
complete, and the medium aspirated out. 0.4 ml of DMSO was added to each well to 
dissolve formazan crystals and then pH adjusted for dye measurement by adding 100 Pl 
of Sorensen’s glycine buffer ( 0.1M glycine, 0.1 M NaCl, pH 10.5).  100 Pl aliquots were 
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transferred to 96-well ELISA plates and the O.D. of each well measured at 570 nm in a 
Tecan Infinite M200 plate reader (Figure 27). 
 
Figure 27: MTT assay data of proliferative rate between Test (GATA-1 siRNA) and 
Control (scrambled siRNA) cells: Doxycycline or minocycline treatments did not show 
statistically significant changes. The experiments were carried out 2 weeks after 
establishment of cell clones. A repeat study with well established clonal isolates (2-3 
month) may be necessary to evaluate the efficacy of this tet-regulated induction system 
both in vitro and in vivo.  Due to time constraints we could not complete these studies, 
but are planned as future research (we may utilize more advanced tet-regulated 
systems that have been introduced by several biotechnology companies during the last 
year). Averaged data from each of the six individual control or test lanes are shown; 
Average decrease in proliferative rate (Control - Doxycycline) = 3.20% ± 0.02; p = 0.35; 
(Control – Minocycline) = 3.13% ± 0.02; p= 0.56. (Test - Doxycycline) = 3.60% ± 0.02; p 
= 0.68; In contrast, an increase in proliferation was seen for minocycline treated test 
cells; (Test – Minocycline) = 6.88% ± 0.02; p = 0.00.  Data analysis was done in 
collaboration with Michael Monterey and Dr. Mathupala. Data were tabulated with 
SigmaPlot 8.0 software (SPSS Inc., Chicago, IL).  
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CHAPTER 3 
OVER-EXPRESSION OF GATA-1 IN GLIOBLASTOMA: AN IN VITRO STUDY 
Introduction 
In the previous chapter, our plan was to address the effects of silencing GATA-1 
on proliferation of U87-MG glioma cells.  Here, we have taken the opposite approach, 
i.e., overexpressing GATA-1 in the same line to test for the effects on cell proliferation, 
changes in metabolism related to glycolysis, i.e., lactate metabolism (efflux), and to test 
for influence of GATA-1 expression on MCT-2 promoter regulation.  Based on the 
positive results we obtained for these objectives, we then proceeded to test the effects 
of GATA-1 over-expression on cell cycle progression in the glioma cells, which also 
yielded novel results. 
Attempts to Over Express GATA-1 via Exposure of Glioma Cells to Erythropoietin 
(Epo)  
Previous investigators have established that the Epo receptor is expressed in U-
87MG glioma cells (Acs et al., 2001).  Thus, our first attempt was to overexpress GATA-
1 in the same cells by exposure of the cells in vitro to Epo.  We obtained recombinant 
human Epo from Sigma chemical company and exposed U87-MG glioma cells growing 
under exponential culture conditions in both low glucose (5 mM) DMEM media as well 
as hi glucose (25 mM) DMEM/F12 media supplemented with either 1% or 5% FBS, to 
test for induction of GATA-1 upon exposure of the cells to Epo.  In brief, the cells were 
exposed to between 0 to 10 pM Epo for 5 days in culture (Kitamura et al., 1989) and 
then cell extracts prepared as described in Chapter 2. 20 to 40 Pg of total protein were 
resolved on SDS-PAGE gel (10%), and western blotted with polyclonal antibody against 
GATA-1 (Novus Biologicals, CO).  However, we could not see changes in expression in 
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any of the Epo/serum combinations that were tested by us (data not shown).  Thus, we 
decided to take a molecular biological approach, where GATA-1 expression was driven 
by a strong viral promoter. 
Overexpression of GATA-1 in U87-MG Cells via Transfection with a GATA-1 
Expression Vector  
In order to overexpress GATA-1 we obtained an expression ready GATA-1 clone 
from Invitrogen Inc. (GeneStorm Expression Ready Clone, in pcDNA 3.1 vector) (Figure 
28).  Plasmid DNA was prepared from E. coli DH5alpha harboring the vector by 
standard plasmid mini-prep procedures (Qiagen MiniPrep) and 2.5 Pg of plasmid 
containing the GATA-1 expression cassette or naked pcDNA3.1 vector were transfected 
into U87-MG cells using Lipofectamine-2000 (Invitrogen) using standard procedure 
described in Chapter 2.  The transfections were carried out in 60 mm tissues culture 
plates, and 24 hrs post-transfection, trypsinized and replated in 100 mm diameter plates 
in DMEM low-glucose medium supplemented with 100 Pg/ml Zeocin as the selection 
antibiotic.  The cells were maintained for two weeks with media changes every 3-days 
to select for cell clones.  6 each of individual clones were selected with cloning cylinders 
as described before (Mathupala and Sloan, 2009) and placed in 6-well plates.  After 
further culture in Zeocin media, cell extracts were made with untransfected U-87MG, 
those transfected with pcDNA3.1 and with vector harboring GATA-1 expression 
cassette.  
A nuclear extract from K-562 erythroleukemia cells (Active Motif, CA) was used 
as a positive control during western blotting, as these cells highly express GATA-1 
endogenously. 
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Figure 28: Schematic for GeneStorm expression ready GATA-1 clone vector 
(Invitrogen, Inc.) used to overexpress GATA-1 in our U-87MG cells. The Pcmv is a very 
strong viral promoter that constitutively expresses GATA-1 protein. Ampicillin was used 
to select for the plasmid in e. coli and G-418 (a neomycin analog) was used in 
mammalian cells (U-87MG) 
As can be seen from the western blot method using Quantum Dots has been 
described in Chapter 2), the selected cell clone that harbored a GATA-1 expression 
cassette show clear overexpression of GATA-1, and this coincides with the GATA-1 
band from the positive control (K-562 nuclear extract).  Also, both the untransformed 
U87-MG cells as well as the control cells that harbor the naked pcDNA3.1 vector show 
similar levels of GATA-1 expression.  Thus, the cell lines could be used in the following 
assays to test for biochemical changes in the cells due to GATA-1 (Figure 29). 
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Figure 29: Coomassie blue dye of native SDS-PAGE gel (left) and western blot for 
GATA-1 protein (right) demonstrating overexpression of GATA-1 protein in test U-87MG 
cells harboring our expression ready GATA-1 plasmid. Increased GATA-1 correlates to 
our nuclear extract positive control. MW = molecular weight marker, NE = nuclear 
extract, U87 = U-87MG cell lysates, C = Control plasmid insert, T = Test plasmid insert. 
MTT Assay for Cell Proliferation 
To test for effects of GATA-1 overexpression, both control and test cells were 
plated in DMEM media lacking phenol-red, in 24-well plates at 0.3 x 10^6 cells per well.  
Post 72 hrs plating, the media were aspirated and fresh pre-warmed media containing 
MTT at 0.5 mg/ml, according to established protocols (Freshney, 2005).  The cells were 
incubated for 90 minutes in the tissue culture incubator until formazan formation was 
complete, and the medium aspirated out. 0.4 ml of DMSO was added to each well to 
dissolve formazan crystals and then pH adjusted for dye measurement by adding 100 Pl 
of Sorensen’s glycine buffer (0.1M glycine, 0.1 M NaCl, pH 10.5). 100 Pl aliquots were 
transferred to 96-well ELISA plates and the O.D. of each well measured at 570 nm in a 
Tecan Infinite M200 plate reader. 
    MW       U87    C     T MW NE    U87    C      T 
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Figure 30: MTT proliferation assay of U87-MG cells transfected with either pcDNA 
containing vector (control) and GATA-1 containing vector (test). There is demonstrated 
a 1.9-fold increase in proliferation of the test U-87MG cells compared to the control 
group, indicating that GATA-1 overexpression enhances tumor cell proliferation. 
 
The data were calculated in quadruplicate and indicate approximately 1.9-fold 
enhancement in proliferation with the GATA-1 overexpressed cell clone.  Thus, the data 
indicate that overexpression of GATA-1 provides a significant advantage to tumors in 
enhancing their proliferation (Figure 30). 
Cell Cycle Analysis 
For this study, the cells were grown as above, in DMEM medium supplemented 
with 10% FBS, and the cells harvested in exponential culture by trypsinization.  The 
cells were resuspended in the same media for the cells to recover from trypsin 
treatment, and then processed for cell cycle analysis by flow-cytometry. 
We set up cultures of normal U-87MG cells, U-87MG cells transfected with the 
control plasmid, and cells transfected with our test plasmid that overexpresses GATA-1.  
Cells were harvested and counted to 1 x 106 density, then centrifuged at 1200 rpm for 5 
minutes.  The pellet was resuspended in 1 ml of 70% ethanol and fixed at 4o C for 30 
minutes. The cell suspension was then respun at 2000 rpm for 5 minutes.  The pellet 
was resuspended in 1 ml PBS and spun at 3000 rpm in refrigerated centrifuge.  This 
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process was then repeated twice.  100 µl of 100 µg/ml RNase was added and incubated 
for 5 minutes. 400 µl of 50 µg/ml propidium iodide was then added and the samples 
were run through the flow cytometer with a488 nm light source triggered on the 
propidium iodide signal.  Samples were first gated by forward scatter against right angle 
light scatter (Figures 31, 32, 33, 34). 
The large population of cells in both diploid and tetraploid states may reflect the 
extremely aggressive nature of these tumors.  Perhaps the most alarming fact is that 
GATA-1 overexpression leads to a greater population of already extremely malignant 
cells (namely, wild-type U-87MG) to enter states that may make them even more 
malignant, in that these tumor cells are now more adept at survival in highly unfavorable 
intratumoral environments (Castedo et al., 2006). 
 
 
Figure 31: Diploid cell cycle analysis from flow cytometry data for normal U-87MG cells 
(above) and cells transfected with our control plasmid (below). There is not much 
difference between the control and wild type cell populations with regard to diploid 
populations, ensuring that the control plasmid did not affect the cell cycle and is 
therefore a good control. 
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Figure 32: Diploid cell cycle analysis from flow cytometry data for U-87MG cells 
transfected with our GAT-1 overexpression plasmid. There is a large increase in the 
diploid population of cells in this group as shown by the second red peak. Furthermore, 
there is a tetraploid peak at 160. This demonstrates that GATA-1 overexpression has a 
positive effect on cell survival and resists programmed cell death. 
 
 
 
Figure 33: Tetraploid cell cycle analysis from flow cytometry data for U-87MG cells 
transfected with our GAT-1 overexpression plasmid. Again seen here is the large 
increase in the diploid population of cells in this group, demonstrating that GATA-1 
overexpression has a positive effect on cell survival and resists programmed cell death. 
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Figure 34: Tetraploid cell cycle analysis from flow cytometry data for U-87MG cells 
transfected with our GATA-1 overexpression plasmid. The tetraploid peak is apparent 
here (furthest right green peak), indicative of rampant cell proliferation. This is especially 
alarming because this may be a sign of increasing aggressive behavior of these already 
malignant tumor cells. 
Lactate Efflux by GATA-1 Overexpressing U87-MG 
This experiment was done to test whether the GATA-1 overexpressing cells have 
enhanced capacity for glycolysis, i.e., enhanced efflux of lactic acid, as this would 
support our hypothesis that GATA-1 promotes the malignancy of the tumor. 
 
Figure 35: Schematic for enzymatic cycling assay for lactate using NADH/NAD+ 
absorbance. LDH = Lactate dehydrogenase; LOD = Lactate oxidase (microbial) 
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Thus, culture supernatants from cells grown in DMEM/F12 media supplemented 
with 10% FBS (a high glucose concentration was used to maximize the glycolytic flux 
across cells for this study) were harvested from both control and test cells, and 
subjected to analysis for lactate (Mathupala et al., 2004).  In brief, 10 Pl aliquots of the 
supernatants (the culture medium was replenished 24 hrs before measurement so that 
the lactate that was accumulated since cells were plated was not assayed) were 
assayed for lactate using a cyclic assay system (Valero and Garcia-Carmona, 1996).  
The assay system consisted of 1.0 ml of the following; 0.94 ml of 50 mM Tris, pH 7.6, 2 
Pl of lactate dehydrogenase (1U/Pl) Sigma, lactate oxidase (0.25 U/Pl), and beta NADH 
(3.6 mg/ml).  The disappearance of NADH was measured at 340 nm to calculate the 
amount of lactate in the culture supernatant. 
 
Figure 36: Assays done at 340 nm to detect loss of absorbance by NADH upon 
conversion to NAD+ 
The results here indicated an enhancement of lactate efflux of approximately 
44% during the 24 hr period when the cells were cultured in DMDM/F12 media 
containing 25 mM glucose.  Thus, a significant enhancement in lactate efflux was seen 
when GATA-1 was overexpressed, indicating a true physiological enhancement of 
glucose metabolism due to GATA-1 expression in these glioma cells.  It is highly likely 
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that other metabolic routes, or the expression of other enzymes that are key to central 
metabolic pathways are also affected by GATA-1 overexpression, to impart such an 
increase in lactate efflux, as simply increasing MCT2 gene expression via GATA-1 may 
not, by itself, lead to such a pronounced increase in lactate efflux.  The above result 
opens up additional avenues to investigate about the metabolic paths that may be 
central to glioma proliferation and survival. 
 
Figure 37: Lactate efflux rates of control and GATA overexpressed (OE) U-87MG 
glioma cells in high glucose DMEM/F12 media (25mM). The extracellular lactate levels 
were measured and divided by the cell count for each experiment to obtain the lactate-
per-cell ratio. Values for the controls were arbitrarily adjusted to 1.00 (average of 6 
experiments). The GATA-1 over-expressed cells showed a 1.44-fold increase in lactate 
efflux (1.44 ± 0.36; p = 0.0140). The cells were plated in 100 mm diameter tissue culture 
plates followed by a media change at ~ 50% confluency. The extracellular lactate was 
assayed 24-hrs later. Cells were then trypsinized and enumerated using a Coulter 
counter. 
Luciferase Reporter Gene Analysis 
For this study, the 4.2 kbp proximal promoter of MCT-2 (described in the 
introduction under Preliminary Data) was cloned into pGL2 Basic luciferase reporter 
gene vector (Figure X,.Promega, WI).  In brief, the proximal promoter of MCT2 and part 
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of the first exon (untranslated region) were cloned into the multicloning site (MCS) of the 
pGL2-basic vector at the KpnI and Hind III sites (the KpnI site was available 5’ to the 
promoter insert in the multicloning site of the original pUC18 clone of  the promoter, 
while a HinD III site was available in the first exon of the MCT2 promoter).  
For the cloning, both pGL2 basic vector and the pUC18 vector harboring the 4.2 
kbp proximal promoter were cultured in E. coli SCS110 (methylation deficient) and 
plasmid isolated with Qiagen Plasmid MiniPrep kit.  The plasmids were double digested 
with KpnI and HinD III (from New England Biolabs, using the recombinant plasmid was 
digested in NEB buffer 2, which is compatible with both enzymes).  After a 2 hr 
digestion at 37oC, the digests were resolved by 0.8% agarose gel electrophoresis, and 
the primary bands (4.2 kbp for promoter and 5.6 kbp for pGL2-basic) were excised, and 
the DNA released by processing via Qiagen Qiaquick Gel purifications kit into 50 Pl / 50 
mM Tris, pH 8.5. 
 
Figure 38: Reporter gene vector used for analysis of MCT-2 promoter activity from 
Promega. 
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3.5 Pl aliquots of each were ligated together in a 10 ml reaction volume with T4 
DNA ligase (1 U) at 13o C in an overnight incubation.  0.5 ml of the ligation was use to 
transform electrocompetent SCS110 E. coli cells using an Eppendorf 2510 
electroporator (18,000 V/cm field strength), and the cells recovered in S.O.C. media for 
1 hour.  The cells were then plated in LB-ampicillin agar plates (50 Pg/ml ampicillin) and 
single colonies isolated after overnight incubation at 37oC.  Plasmid DNA was prepared 
from the clones as before using Qiagen Miniprep kits and insert verified by DNA 
sequencing.  
Subsequently, nested deletion mutants were made of the luciferase reporter 
plasmid to generate a 3 kbp proximal promoter clone and a 2 kbp proximal promoter 
clone (made by Dr. Mathupala and clones isolated by Mr. Phil Benson).  In brief, the 
MluI site on pGL2 Basic vector (resistant to digestion with Exonuclease III) and MluI site 
(sensitive to Exonuclease III digestion) was used to prepare the deletion mutants in a  
timed digestion reaction (Sambrook and Russell, 2001). 
These plasmids, along with a control luciferase plasmid based on Renilla 
luciferase were used to test for promoter activation using the Dual-Glo luciferase Assay 
system according to the manufacturer’s instructions. In brief, 1.2 x 106 U87MG glioma 
cells (either the control cells or, GATA-1 overexpressing cells) were first mixed with 1 Pg 
Renilla luciferase plasmid vector (this vector normalizes transfection efficiency across 
all reactions involving the MCT2 promoter-pGL2 basic vector based transfections in 
steps described below.  Then, the mix was aliquoted into three, and 9 Pg equivalent of 
basic vector (with no promoter), the 3 kbp promoter, or the 2 kbp promoter was mixed 
into the individual aliquots.  Equimolar amounts of the promoter was used in the 
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transfections.  The transfections were completed in DMEM-Basal medium (no serum 
present), in the presence of lipofecamine-2000 under the same conditions described in 
Chapter 2, and plated into wells of a 24-well plate (5 x 104 cells per well; 8 wells per 
vector).  6 hrs post transfection, media in wells were changed to DMDM/F12 (phenol red 
free medium) supplemented with 10% FBS. 72 hrs post-transfection, the media was 
aspirated, and the cells lysed in lysis buffer (Dual Glo Luciferase reagent) provided by 
manufacturer (250 Pl per well), aliquoted 50 ml per well in a white-wall 96-well plate and 
then assayed for firefly luciferase activity (bioluminescence setting, Tecan Infinite M200 
plate reader).  Subsequently, the firefly luciferase activity was quenched by a 
substrate/reaction condition change (Dual-Glo Stop and Glo Reagent) by adding 50 Pl 
to each well, and then assayed for Renilla luciferase, to normalize the transfection 
efficiencies across the three sets of experiments. 
Then, the data were calculated by dividing the firefly luciferase reading with the 
reading for Renilla luciferase, to identify any changes in MCT2 promoter activation. 
Based on the results we can see an approximate 3.3 fold activation is seen with 
the 2 kbp promoter while a 1.9 fold activation is seen with the 3 kbp promoter, thus 
clearly indicating promoter activation upon the presence of GATA-1.  Furthermore, the 
results clearly correlate with the lactate assay studies described previously, proving our 
overall hypothesis of the involvement of GATA-1 in enhancing glioma metabolism and 
proliferation. 
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Figure 39: Reporter gene activation of two nested deletion mutants of the 4.2 kilobase 
pair proximal MCT-2 promoter. Two deletion constructs were used: one 3 kbp and the 
other 2 kbp. A 1.9-fold increase in promoter activity was seen for the 3 kbp proximal 
promoter region (1.9 ± 0.08; p = 0.04), while a 3.13-fold increase was seen for the 2 kbp 
proximal promoter region (3.13 ± 0.06; p = 0.004). 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
GATA-1 influences the Monocarboxylate Transporter-2 (MCT-2) Expression 
Resulting in Altered Glycolytic Capacity in GBM Cells 
The overall goal of my thesis research was to elucidate whether changing the 
expression levels of GATA-1 in the model GBM cell line under study, U87-MG glioma, 
would in turn alter the MCT-2 expression levels (based on the presence of GATA-1 
response elements on the proximal promoter of  MCT-2, and to test whether this would 
have direct influence on the glycolytic flux across the GBM cells.  It is primarily this 
metabolite flux that maintains the high proliferative capacity in malignant tumors and 
any changes to the flux should have a significant influence on the tumor growth in vitro, 
which would relate to any altered growth rate in an in vivo tumor model, or in a brain 
tumor patient. 
We began our project by taking a closer look at GATA-1, a transcription factor 
that was previously believed to only participate in blood cell maturation before it was 
discovered to be present in very high levels in GBMs (both in cell culture and from de 
novo surgical specimens).  We set out to examine what would happen to GBM 
metabolism and proliferation if levels of GATA-1 protein were decreased and increased.  
We used host cell machinery to degrade mRNA transcripts of GATA-1 using carefully 
chosen, most optimum shRNA against GATA-1.  We selected this shRNA from a pool of 
4 possible siRNA sequences specific only to the GATA-1 gene.  We demonstrated 
through lipofection of U87-MG cell cultures that siRNA sequences were all successful at 
decreasing the levels of GATA-1 protein in these cells, and that sequence #4 was the 
most efficient one.  We then engineered a stable U-87MG cell line (via virus-mediated 
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transformation) capable of producing shRNA against GATA-1 in response to 
administration of tetracycline to the media.  We accomplished this by using the Clontech 
tet-on/off plasmid system.  After down-regulating GATA-1, we examined the effect that 
this had on synthesis of MCT-2 in GBMs and on cell metabolism and proliferation. 
The next phase of this work was, in essence, the opposite of the first. We used a 
different set of plasmid vectors to constitutively express GATA-1, thereby creating in our 
U-87MG cells a state of GATA-1 over-expression.  We looked at several different 
aspects of GBM metabolism in these U-87MG cells, including the rate of lactate efflux 
through MCTs, cell cycle analysis, cell proliferation rates, and reporter gene analysis of 
the MCT-2 gene. 
Long-term GATA-1 overexpression data presented in Chapter 3 showed 
significant enhancements in both glycolytic flux (lactate efflux) and MCT-2 expression 
(western blot analysis), as well as enhanced proliferation of GATA-1 overexpressing 
U87-MG cells (MTT assay), thus supporting our overall hypothesis.  The observed high 
rate of lactate efflux may be due to GATA-1 influencing not only the levels of MCT-2 but 
other enzymes along the glycolytic pathway (yet to be identified as being modulated by 
GATA-1). 
The overall goal of the project was to test whether we can inhibit the glycolytic 
rate of GBMs via RNAi mediated methods and if so, whether that would be applicable in 
an in vivo setting (animal model), and in a future clinical setting.  The preliminary results 
from Chapter 2 indicate that RNAi mediated methods may not be sufficiently strong for 
complete silencing of GATA-1 expression, at least in the GBM model used, or perhaps 
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the engineered cells (with GATA-1 silenced) need to be tested for a longer period of 
time (multiple rounds of cell divisions).  
An alternative method would be to inhibit GATA-1 via small molecule drugs, 
which are currently being developed by a pharmaceutical company in Japan (Kawa Co., 
Japan).  These may be a suitable alternative to RNAi mediate silencing of GATA-1, or 
may be useful in combination therapies with other metabolic targeting small molecule 
drugs to inhibit GBMs. 
The Influence of GATA-1 on Tumor Growth has already been Acknowledged by 
the FDA 
As mentioned in the introductory chapter, GATA-1 plays a key role in erythrocyte 
development and maturation. GATA-1 knockout mice are unable to produce any mature 
red blood cells and production and maturation of other blood cells (including 
megakaryocytes, platelets, and eosinophils) is severely hindered.  Recall, as well, that 
GATA-1 has been linked to anti-apoptotic proteins such as Bcl-XL, cell cycle core 
components, the erythropoietin receptor, and other proliferative genes.  When the NIH 
grant that the research is based on was first submitted in 2004, we proposed based on 
the preliminary studies outlined in Chapter 1 (preliminary data on GATA-1 
overexpression in GBMs), that use of erythropoietin to treat anemia in brain tumor 
patients may be counterproductive, as it would lead to Epo dependent enhancement of 
GATA-1 levels in these tumor leading to more aggressive tumor growth. 
This fact has now been acknowledged by the FDA in 2006, when they released a 
“black-box” warning on the use of Epo on patients with ”head-and-neck” cancers.  Thus, 
the clinical applicability of our studies on tumor patients is quite evident from such 
warnings (Figure 40). 
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Figure 40: FDA black-box warning for Epogen (epoetin alfa) warning of the tendency of 
this drug to increase mortality of cancer patients and lead to accelerated tumor 
progression. Since erythropoietin has been shown to up-regulate GATA-1 levels during 
red blood cell maturation, one of the likely mediators of this phenomenon is GATA-1, 
likely up-regulated by the drug. (online.epocrates.com/u/10b2027/Epogen/Black+Box+Warnings) 
Future Directions 
As planned at the outset of my project, the in vitro studies outlined in the thesis 
will be expanded further to include RNAi studies on a long-term basis and then will be 
tested in vivo (RNAi mediated silencing and its effect on tumor proliferation) using the 
tet-regulated systems in an orthotopic nude rat model.  We were unable to complete the 
in vivo studies due to both time constraints and technical difficulties at the time.  Thus, 
the goal is to repeat those studies first in vitro using the same Tet-based system or 
alternate (more recent, upgraded) systems, and evaluate the effects of GATA-1 
silencing on a long term basis in vitro, and then transfer the experimental system to an 
in vivo nude rat model for long term studies. 
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As discussed earlier, small-molecule drug candidates are under development 
(GATA-1 antagonists), and if these become available for preclinical studies they can 
also be tested in parallel with our other future studies outlined above. 
In conclusion, our finding that GATA-1 is overexpressed in GBMs was novel, and 
paves the way for an addition to be made to the repertoire of currently available 
therapeutics in use against brain tumors in a future clinical setting. The research that 
was concluded in the thesis project clearly indicates a direct correlation between this 
transcription factor, formerly known to be only involved in erythropoiesis, and glycolysis, 
a key metabolic pathway crucial for tumor proliferation and survival. 
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Degree: Doctor of Philosophy 
Introduction: Malignant glioma display a highly glycolytic phenotype where the 
tumors flux glucose to lactic acid independent of oxygen concentration (“aerobic 
glycolysis”).  This altered phenotype is facilitated by expression of primarily fetal 
enzyme isoforms in these malignant tumors.  The end-product lactic acid is rapidly 
expelled from the cytosol by selective monocarboxylate transporters expressed on the 
plasma membrane. GATA response element islands are present on the promoter of 
glioma lactate transporter genes, and GATA-1 has been shown to be over-expressed in 
glioblastoma. Our long-term goal is to inhibit glioma proliferation by indirectly down-
regulating GATA-1 to inhibit glycolysis (Colen et al., 2006; Mathupala et al., 2007; 
Mathupala et al., 2004). 
Methods: We have engineered U87-MG glioblastoma tumor cell lines to either 
over-express (via viral promoter based vectors) or silence (using siRNA inducible vector 
systems) GATA-1. Cell proliferation was assessed via both MTT assay and cell cycle 
analysis.  Luciferase based reporter gene analysis was utilized to identify regulation of 
lactate transporter promoter by GATA-1. 
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Results:  Western blot analysis indicated up- and down-regulation of GATA-1 via 
the appropriate vector system.  Up- or down-regulation of GATA-1 either enhanced or 
reduced the proliferative rate and the lactate transporter promoter activity. 
Conclusions: Regulation of GATA-1 directly impacts glycolytic metabolic flux 
and proliferation of malignant glioma.  Thus, small molecule drugs against GATA-1 may 
be used as an adjuvant therapy for metabolic targeting of malignant glioma. 
KEYWORDS: Glioma, Lactate transporter, GATA 
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